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Abstract 
The last few decades have provided stunning progresses in the understanding of 
physiopathology of several diseases. The remarkable progress in research fields, like 
genetics, immunology, neurobiology, among others, as well as the advent of more 
powerful tools, have made it possible to characterize, monitor, and understand far more 
of the basis of physiology and disease. However, for some diseases the treatment 
remains a problematic issue as the efforts performed so far were not translated into 
therapeutic solutions. Notwithstanding the steady increase in the total amount of 
money spent on pharmaceutical research and development over the past decade, the 
number of new drug approvals has declined in recent years. Despite the advances in 
technology, drug discovery is still a lengthy, expensive, difficult, and inefficient process, 
with a low rate of success. Therefore, the search for new chemical entities is still an 
unmet need for the drug discovery process.  
Application of new drug discovery approaches/concepts for multifactorial 
diseases, such as cancer and neurodegenerative diseases, have prompted a switch on 
the strategy of one-molecule one-target to a new one, the multi-target approach, where 
a single chemical entity may be able to modulate multiple targets simultaneously.  
In the present project, the main challenges were the validation of chromones as a 
privileged structure for the design of new drug candidates for Parkinson disease and 
the development dual-target lead compounds. Accordingly, the design of a chromone 
library to attain structure-activity relationships and the development of concise and 
diversity-oriented synthetic strategies has been carried out along this project. The small 
but innovative chromone libraries were screened to ascertain their potential as MAO-B 
inhibitors as well as A2A adenosine receptor ligands. The output of the biological 
screening assays gave rise to preliminary structure-activity relationship regarding both 
of the targets. The overall data showed that chromones are privileged structures for 
drug discovery and development processes in the field of Parkinson disease and that 
chromone-3-(3‘-hydroxy-4‘-methoxyphenyl)carboxamide and chromone-3-(4‘-
chlorophenyl)carboxamide, exhibiting a IC50 for hMAO- B in a nanomolar range and 
affinity towards A2A ARs, can be regarded as putative leads for further optimisation. In 
addition, during the drug discovery process interesting A3 AR ligands based on 
chromone scaffold have been found, namely chromone-2-carboxamides such as the 
chromone-2-(4‘-methoxyphenyl)carboxamide which presented a Ki value for hA3 AR of 
9,580 nM and reasonable to good selective indexes regarding the other ARs ligands.  
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Complementarily, the work described along this thesis was sustained on 
molecular docking studies performed over MAOs isoforms and ARs, for the most active 
chromone derivatives. 
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Resumo 
As últimas décadas têm sido pautadas por um impressionante progresso em 
áreas como a genética, imunologia, neurobiologia, entre outras. O crescente 
conhecimento científico, bem como o desenvolvimento de novas e mais potentes 
tecnologias, tornaram possível não só a caracterização e monitorização dos processos 
fisiológicos mas também uma maior compreensão dos processos patológicos de 
inúmeras doenças. No entanto, para algumas enfermidades os esforços até agora 
realizados não conseguiram ser traduzidos em soluções terapêuticas.  
O processo de descoberta e desenvolvimento de novos fármacos é dispendioso, 
demorado e com uma baixa taxa de sucesso De facto, e apesar do crescente 
investimento económico por parte da indústria farmacêutica, o número de novos 
fármacos tem diminuído ao longo das últimas décadas. Neste contexto, a descoberta 
de novas entidades químicas (NCEs), candidatas a novos fármacos, continua a ser um 
tópico da maior relevância na química medicinal.  
No caso das doenças de natureza multifatorial, como cancro e eventos 
neurodegenerativos, o processo de descoberta e desenvolvimento de novos fármacos 
é ainda um desafio. Numa tentativa de acelerar o processo assiste-se actualmente a 
uma modificação da estratégia do desenho racional de fármacos com passagem do 
paradigma ―uma molécula-um alvo terapêutico‖ para uma abordagem multi-alvo, onde 
uma única entidade química tem ser capaz de modular, simultaneamente, mais do que 
um alvo. 
O presente projeto consistiu na validação da cromona como uma estrutura 
privilegiada para a descoberta de novos candidatos a fármacos para a doença de 
Parkinson e no desenvolvimento de compostos líder com um mecanismo de acção em 
dois alvos terapêuticos. Neste contexto procedeu-se à obtenção e desenvolvimento de 
estratégias sintéticas para a construção de pequenas e inovadoras bibliotecas 
baseadas no núcleo da cromona. Adicionalmente, foram efetuados estudos para 
avaliação do seu potencial como inibidores da MAO-B e ligandos do recetor A2A da 
adenosina. Os resultados obtidos foram interpretados através do estabelecimento de 
relações de estrutura-atividade e em estudos de modelização molecular, envolvendo 
as isoformas da MAO e os recetores da adenosina. os quais foram realizados para os 
derivados de cromonas mais potentes.  
Os dados obtidos até à data permitiram concluir que a cromona pode ser uma 
estrutura privilegiada para a descoberta e desenvolvimento de novos fármacos para 
doença de Parkinson. Do estudo efectuado salienta-se os resultados obtidos para dois 
derivados da cromona sintetizados, nomeadamente a cromona-3-(3'-hidroxi-4'- 
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metoxifenil)carboxamida e a cromona-3-(4'-clorofenil)carboxamida, os quais exibiram 
um CI50 para hMAO-B na ordem dos nanomolar e afinidade relevante para o recetor 
A2A da adenosina. Estes compostos, após uma etapa subsequente de otimização, 
podem produzir candidatos inovadores, com um mecanismo de ação duplo-alvo, e 
uma nova solução terapêutica para a doença de Parkinson. Salienta-se ainda os 
resultados obtidos para uma biblioteca de cromonas (cromona-2-carboxamidas), as 
quais evidenciaram, de uma foram geral, uma afinidade relevante para os recetores A3 
da adenosina, nomedamente a cromona-2-(4'-metoxifenil)carboxamida a qual  
apresentou um valor de Ki = 9,580 nM para o referido recetor. Os dados obtidos, 
assim como a seletividade apresentada, leva a considerar este tipo de derivados de 
cromonas compostos passíveis de ser otimizados para o desenvolvimento de novos 
anticancerígenos. 
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Abbreviations  
Ach – Acetylcholine  
AChE – Acethylcolinesterase  
Amino acids:  
Asn – Asparagine 
Cys – Cysteine 
Gln – Glutamine 
Glu – Glutamic acid 
His – Histidine 
Ile – Isoleucine 
Leu – Leucine 
Phe – Phenylalanine 
Ser – Serine 
Thr – Threonine 
Trp – tryotophan 
Tyr – Tyrosine 
Val – Valine 
ARs – Adenosine receptors 
BOP – O-Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate  
CNS – Central nervous system  
COMT – Catechol-O-methyltransferase  
COSY – Correlation spectroscopy 
DA – Dopamine  
DBU – Diazabicyclo[5.4.0]undec-7-ene  
DOPAC – Dihydroxyphenylacetic acid  
EI/MS – Electron Impact Mass Spectrometry 
EL – Extra loop 
GABA – Gamma aminobutyric acid  
GP – Globus pallidus,  
GPCRs – G protein coupled receptors 
GPe – Globus pallidus pars externa  
GPi – Globus pallidus pars interna  
hA1 AR – Human adenosine subtype A1 receptor 
hA2A AR – Human adenosine subtype A2A receptor 
hA2B AR – Human adenosine subtype A2B receptor 
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hA3 AR – Human adenosine subtype A3 receptor 
hMAO-A  – Human monoamine oxidase type A isoform 
hMAO-B – Human monoamine oxidase type B isoform 
HMBC – Heteronuclear multiple bond correlation 
HMPA – Hexamethylphosphoramide  
HMQC – Heteronuclear multiple quantum coherence 
HTS – High-throughput screening  
HVA – Homovanillic acid  
IL – Intra loop 
L-AAD – L-Aromatic amino acid decarboxylase or dopa decarboxylase  
L-dopa – L-Dihydroxyphenylalanine  
MAO-A – Monoamine oxidase type A isoform 
MAO-B – Monoamine oxidase type B isoform 
MPP+ – 1-Methyl-4-phenylpyridinium ion 
MPTP – 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NCEs – New chemical entities 
NMR – Nuclear magnetic resonance 
PD – Parkinson‘s disease  
PyBOP – O-Benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate  
PyBrOP – Bromotripyrrolidinophosphonium hexafluorophosphate  
SARs – Structure–activity relationships  
SN – Substantia nigra  
SNr – Substantia nigra pars reticulata  
STN – Subthalamic nucleus  
TH – Tyrosine hydroxylase  
Metric units  
µg – Microgram 
µL – Microliter 
µM – Micromolar 
g – Gram 
K – Degrees Kelvin  
L – Litre 
M – Molar 
mg – Milligram 
min – Minute 
mL – Mililiter 
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mM – Milimolar 
ng – Nanogram 
nL – Nanoliter 
nM – Nanomolar 
ºC – Degrees Celsius  
ppm – Parts per million 
Symbols 
δ – Chemical shift in ppm 
d – Duplet 
dd – Double duplet 
ddd – Double double duplet  
J – Coupling constant 
m – Multiplet 
m/z – mass charge ratio 
s – Singulet 
t – Triplet 
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1.1 Introduction 
The Committee of the International Union of Pure and Applied Chemistry 
(IUPAC) defines medicinal chemistry as ―a chemistry-based discipline, also involving 
aspects of biological, medical and pharmaceutical sciences. It is concerned with the 
invention, discovery, design, identification and preparation of biologically active 
compounds, the interpretation of their mode of interaction at the molecular level, the 
construction of their structure-activity relationships, and the study of their  
metabolism" [1]. The interdisciplinarity between Chemistry and Biology, essential for 
medicinal chemistry, was brilliantly recognized by Arthur Kornberg, a Nobel laureate, in 
1959 who wrote: ―We have the paradox of the two cultures, chemistry and biology, 
growing further apart even as they discover more common ground.” [2]. Due to the 
harmonization of these apparently distinct two sciences, conditions have been created 
for the growth of medicinal chemistry and consequently for drug discovery and 
development processes. 
Nowadays, medicinal chemistry is seen as a science situated at the interface of 
organic chemistry and life sciences, encompassing the knowledge of biochemistry, 
pharmacology, molecular biology, genetics, immunology, pharmacokinetics and 
toxicology on one side, and chemistry based disciplines, such as organic and physical 
chemistry, crystallography, spectroscopy and computer-based techniques, data 
analysis and data imaging on the other side [3].  
Medicinal chemistry is a dynamic science that changes as the drug discovery 
paradigms shifts. Before 1990 the lead generation in the drug discovery processes was 
based on natural ligands and massive synthesis [4-7]. Usually, the therapeutic purpose 
is fixed in advance and a large number (several thousands) of molecules is tested on a 
limited number of experimental models. This method, called as random screening, has 
been used for the discovery of several drugs, particularly antibiotics. The common 
criticism of this type of methodology is that it constitutes, by the absence of a rational 
lead, a sort of fishing.   
The steep increase in the knowledge about biological processes, the factors 
leading to their misregulation and ultimately to disease as well as the development of 
new technologies, such as high-throughput screening (HTS), microwave assisted 
synthesis and parallel and combinatorial technology, have a tremendous impact on the 
methodologies of drug discovery, and correspond to the entrance of a new era - the so-
called ―rational drug design‖. Classically, the drug discovery process embraces four 
stages of: i) target identification (enzyme, receptor, ion channel, signalling protein, 
transport protein or DNA.), ii) target validation, iii) (hit) lead identification and 
optimisation, iv) candidate(s) selection [8]. During the process it is essential to ensure 
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that the molecule is innovative (new chemical entities (NCEs)) and that it reaches its 
target effectively while also ensuring that it satisfies necessary safety requirements.  
Drug design is a complex issue that still lacks a general approach that has 
proven reliability. There is still a need to select the appropriate structural series of 
compounds, to follow and pursue the SARs in order to identify suitable drug candidates 
for advancement to safety and clinical testing [5]. Furthermore, it has become 
increasingly clear that many effective drugs act by interactions with multiple receptors 
and/or enzymes, although they may have been designed to be highly selective.  
For some time, scientists involved in drug discovery have been questioning the 
wisdom of the reductionist philosophy (one drug-one target.) of hitting single targets as 
the accurate approach to ameliorate complex disease states [9]. Although the strategy 
of one-molecule-one-target has led to the discovery of many successful drugs, this 
concept has been recently shifted to a new one, the multi-target approach, where a 
single chemical entity may be able to modulate simultaneously multiple targets. This 
new strategy seems to be of particular interest in areas that involve multiple pathogenic 
factors, like neurodegenerative diseases, diabetes, cardiovascular diseases, and 
cancer [9, 10]. One of the main limitations with this approach is the ability to define the set 
of targets that is causative of a particular disease state and design compounds that will 
hit the key targets with a desirable ratio of potencies. This is certainly a daunting 
challenge. 
However, and despite the remarkable conceptual and technique differences of 
the earlier era of drug discovery, medicinal chemistry faces today many of the 
challenges that it confronted in the past. The accepted paradigm for drug discovery in 
the last 25 years has failed to provide a sufficient number of innovative and effective 
new drugs to continue to fuel the research and development (R&D) engine. Drug 
approvals by the US Food and Drug Administration (FDA) have continued to fall from 
the levels of the 1990‘s. The challenge to select the most druggable targets and to find 
the suitable drug-like molecules, substances that not only interact with the target but 
also have specific pharmacokinetic and toxicological properties, has generated more 
attrition in the process [11].  
Now and again a remembrance of the past appears as a way out. Although 
natural products have been marginalized by major pharmaceutical companies over the 
last 20–30 years, the changing landscape of drug discovery now favours a greatly 
enhanced role for nature‘s privileged structures [12]. Advances in total synthesis, 
especially function-oriented syntheses and biosynthetic technologies offer new 
avenues to the identification and use of privileged structures and molecular fragments 
that are able to interact with more than one target. For nearly 20 years, privileged 
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structures have offered an optimal source of core scaffolds and fragments for the 
design of chemical libraries directed at a broad spectrum of targets [13].  
In summary, although the drug discovery approaches have changed significantly 
over the past 50 years as the workflows have been reinvented, the same goals remain: 
find and test novel molecules that can reach and act on disease targets.  
1.2 Scope of the thesis 
The research program of the thesis was aimed at the discovery and development 
of new chemical entities skilled to be a therapeutic solution for Parkinson‘s disease. 
The main challenges were by one side the validation of the chromone scaffold as a 
privileged structure for the design of new drug candidates for Parkinson´s disease and 
by the other the development of dual-target lead structures. 
Therefore, the specific goals of this thesis were: 
i. Design of a library of structural related chromone derivatives suitable to 
achieve proper structure-activity relationships; 
ii. Establishment of concise and diversity-oriented synthetic strategies 
embedded with the benzopyran motif and development of efficient and 
less time consuming synthetic strategies;  
iii. Biological screening towards MAO-B;  
iv. Assessment of the binding affinities towards adenosine receptors. 
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2.1 Parkinson’s disease 
Parkinson‘s disease (PD) is the second most prevalent neurodegenerative 
disorder, affecting up to 10 million people worldwide[14, 15]. The cardinal 
neuropathological feature of PD is a dopaminergic cell loss within the substantia nigra 
(SN). Despite the enormous amount of research in the field, that reveal the implication 
of some molecular mechanisms such as mitochondrial dysfunction, production of free 
radicals and oxidative stress [16, 17], protein aggregation [18, 19], like α-synuclein 
aggregation [20], neuroinflammation [21], and impaired protein degradation [22],the 
features and sequence of the events that generate the exact causes of cell death in PD 
remain unknown[23]. It is also important to point out that some etiological factors have 
been associated with the disease, namely genetics [24], aging [15] and environmental 
toxins [25, 26].  
Classically, PD is considered a motor system pathological condition with an 
extensive degeneration of the dopaminergic neurons and subsequent dopamine (DA) 
depletion [27]. The histopathological features of PD occur mainly on basal ganglia (Fig. 
2.1), which comprises a group of interconnected deep brain nuclei, namely the 
striatum, formed by the caudate nucleus and putamen, the globus pallidus (GP), the 
substantia nigra and the 
subthalamic nucleus (STN). The 
dopaminergic nigrostriatal 
projections, by modulation of the 
thalamus and the cortex output, 
influence the generation and 
execution of voluntary 
movements. DA also plays a 
crucial role in modulation of 
other basal ganglia 
neurotransmitters associated 
with motor control, like  γ-
aminobutyric acid (GABA), 
acetylcholine (ACh), glutamate, 
enkephalin, and substance P [27-
29].  
The degeneration of the 
nigrostriatal dopaminergic 
neurons with the disruption of the complex circuitry mentioned above can culminate on 
movement disorders, such as those implied on PD [30, 31]. This disease is clinical 
Figure 2.1 Schematic representation of the basal ganglia 
anatomy 
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translated into motor manifestations, such as bradykinesia, rigidity tremor and postural 
instability [27]. In addition to the degeneration and loss of the dopaminergic neurons, the 
neurodegenerative process is also associated with the loss of serotonergic, 
noradrenergic and cholinergic neurons and, consequently, with the depletion of the 
corresponding neurotransmitters [27, 32]. The latter described pathological processes are 
linked with the non-motor manifestations of PD, including cognitive decline, sleep 
abnormalities and depression as well as gastrointestinal and genitourinary 
disturbances [27, 32]. The advent of non-motor complications on PD is well documented 
although often under-recognised in clinical practice and diagnosis, which still relies on 
detection and evaluation of the cardinal motor symptoms [29]. 
2.2 Dopamine biosynthesis and nigrostriatal pathways  
The biosynthesis of DA occurs in the dopaminergic neurons and starts with the 
conversion of the L-tyrosine to L-dihydroxyphenylalanine (L-dopa) by the action of the 
enzyme tyrosine hydroxylase (TH). L-Dopa is then converted into DA by the enzyme L-
aromatic amino acid decarboxylase (L-AAD), also called dopa decarboxylase (Fig. 2.2) 
[33-36]. Once synthesised, DA is sequestered into vesicles and released into the synaptic 
cleft, where it exerts its role by interacting with specific receptors. The DA receptors are 
a class of G protein-coupled receptors (GPCRs), commonly divided in two major 
classes: D1-like receptors, comprising D1 and D5 receptors, and D2 like-receptors class 
formed by the D2, D3, and D4 receptors subtypes 
[37]. The DA metabolism encompasses 
either its reuptake by the dopaminergic neurons or its uptake by glial cells. Briefly, after 
its reuptake by the neurons, DA can be recycled and stored in vesicles, or converted to 
dihydroxyphenylacetic acid (DOPAC) by the action of monoamine oxidase-B (MAO-B) 
and aldehyde dehydrogenase (AD) (Fig 2.2). On the other hand, within glial cells, DA is 
converted into homovanillic acid (HVA) by the action of catechol-O-methyltransferase 
(COMT), MAO-B and AD (Fig. 2.2) [33-36].  
Through its innervation systems, DA acts as a relatively slow modulator of a 
faster neurotransmission mediated by glutamate and GABA, and it has been implied in 
several vital functions of the central nervous system (CNS) such as voluntary 
movement, appetite, affection, reward, sleep, attention, working memory and learning 
[38]. Accordingly, the typical movement disorders observed in PD have been linked with 
the degeneration and loss of basal ganglia dopaminergic projections, specially of the 
dopaminergic nigrostriatal neurons [28, 39, 40].  
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
24 
 
 
Figure 2.2 Schematic representation of dopamine metabolism. L-AAD: L-aromatic amino acid decarboxylase 
AD: aldehyde dehydrogenase, COMT: catechol-O-methyltransferase, DOPAC: dihydroxyphenylacetic acid, 
DOPAL: 3,4-Dihydroxyphenylacetaldehyde, HVA: homovanillic acid, MAO-B: monoamine oxidase-B, TH: 
tyrosine hydroxylase. 
 
The actual model of the basal ganglia circuitry is based in the existence of two 
major projection systems: the direct and indirect pathways. Concisely, the direct and 
indirect pathways arise from different populations of striatal projection neurons, whose 
activity is regulated by striatal dopamine, supplied via nigrostriatal projection from the 
substantia nigra compacta (SNc). The direct pathway (Fig.2.3) encloses D1-like 
receptors, involving dopaminergic projections from the striatum to the globus pallidus 
pars interna (GPi) and substantia nigra pars reticulata (SNr). The indirect pathway 
(Fig.2.3) selectively expresses D2-like receptors and involves the projections of the 
striatum to globus pallidus pars externa (GPe) [37, 39, 41, 42]. It has been postulated that 
movement control by basal ganglia involves both direct and indirect pathways, by 
modulation of the cortical afferent activity through thalamus output.  
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The direct 
pathway is triggered by 
the activation D1 
neurons that project 
mainly to the GPi and 
SNr with subsequent 
inhibition of their 
GABAergic neurons, a 
process which seems 
to enhance thalamo 
cortical circuitry and, 
consequently, facilitate 
movement. The 
dopamine interaction 
with D2 neurons 
triggers the indirect 
pathway by inhibiting 
the GPe GABAergic 
projections directly 
attached with STN. 
This inhibition, results 
in the activation of 
glutamatergic 
projections from STN to 
GPi/SNr enhancing the 
inhibitory effect of 
GPi/SNr over the 
thalamus [30, 39, 42]. 
Thus, the indirect 
pathway activation 
interferes with the 
thalamocortical circuitry 
resulting in a movement inhibition [43].  
More recently, controversial experimental data, led to questioning the consistency 
of the referred model. Although some of its features and hypotheses should be clearly 
reviewed [39, 44], significant assumptions of the basal ganglia circuitry model are still 
widely accepted (e.g. the basic connections between the basal ganglia nuclei and the 
Figure 2.3 Schematic representation of basal ganglia direct and indirect 
pathways. GPe: globus pallidus pars externa, GPi: globus pallidus pars 
interna, SNc: substantia nigra pars compacta, SNr: substantia nigra pars 
reticulata STN: subthalamic nucleus. 
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role of dopaminergic system in the striatum output) [39]. It is also important to point out 
its contribution to the study of the pathophysiology of movement disorders such as the 
ones observed in Parkinson‘s disease. In this neurodegenerative disease the 
regulatory role of DA in striatrum is compromised [27, 29], which leads to a reduced 
activity of the direct nigrostriatal pathway, whereas the indirect nigrostriatal pathway 
activity is increased, resulting in an excessive GPi inhibitory output to the thalamus with 
a consequent movement disorders [28].  
2.3 Parkinson's disease therapy the current status 
Nowadays the pharmacological therapy available for Parkinson's disease (PD) 
aims to improve patients‘ life quality, slowing down the progression of symptoms, either 
through the delay of the physical and psychological morbidity inherent to of the disease 
or by diminishing the long-term complications associated with the therapy [45]. The main 
strategic developments for symptomatic treatment and discovery of new compounds to 
modify the course of PD were focused on the improvement of dopaminergic therapies 
and in the identification of non-dopaminergic drugs. 
Despite all the recent research in the field, there are only a few classes of drugs 
approved for the treatment of the motor related symptoms of PD, namely the ones that 
act primarily on the dopaminergic system, such as L-dopa, dopamine agonists, MAO-B 
and COMT inhibitors, and the non-dopaminergic drugs like anticholinergic and 
glutamate antagonists [45, 46].  
In the fowling sections it will be succinctly presented the current status of the 
available chemotherapy for the treatment of the motor afflictions of Parkinson‘s disease 
will be briefly discussed, as well as the importance of the discovery and development of 
new drugs for PD. 
2.3.1 Dopaminergic treatments for Parkinson´s disease  
2.3.1.1 L-Dopa  
The observation that dopamine levels in the basal 
ganglia of patients suffering from PD were much lower 
than those found in the brains of healthy persons, was 
the key information that boosted the drug discovery for 
PD that lead to the introduction of L-dopa (Fig.2.4) in the market from the late  
1960‘s [47].  
Almost 50 years later, L-dopa remains the most useful oral drug in PD therapy, 
showing real effectiveness in the reversibility of motor limitations of the disease.  
Figure 2.4 Chemical structure of L-
dopa. 
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L-Dopa is a natural dopamine precursor that can cross the blood-brain barrier but 
has a relatively short half-life period of 60 to 90 min [48]. Once in the brain, exogenous 
L-dopa is taken up by dopaminergic neurons, thus mimetizing the endogenous one, 
and converted to DA by the dopa-decarboxylase and stored in vesicles with 
subsequent release into the synaptic cleft. 
The PD progressive loss of dopaminergic neurons, which are required to the 
biosynthesis, metabolism, storage and release of dopamine, influence the beneficial 
effect of each dose of L-dopa by shorting the time of its effectiveness and so the daily 
scheduled dose must be adjusted [47]. The long-term usage of this drug can lead to a 
narrow therapeutic window as well as several complications [49]. Standard treatment of 
PD with L-dopa causes a number of typical peripheral 
and central dopaminergic adverse events, including 
nausea, vomiting, hypotension, hallucinosis, paranoid 
psychosis and particularly iatrogenic dyskinesias [50]. 
Some of the side effects are mainly due the peripheral 
metabolism of exogenous L-Dopa to DA in the liver and 
intestinal mucosa via peripheral L-AAD. In fact, less 
than 1% of administered L-dopa reaches the brain. To 
overcome this drawback a combination of L-dopa with 
L-AAD inhibitors such as carbidopa and benserazide 
(Fig. 2.5) is commonly prescribed. Thus, the L-dopa 
bioavailability is increased and the necessary dose to 
obtain effect reduced as well as the peripheral side effects [51]. 
2.3.1.2 Dopamine agonists 
One of the strategies employed to minimize the side effects of L-dopa is related 
to the use of dopamine agonists. This drugs were launched as first-line effective drugs 
for monotherapy in the early stages of the disease, in order to postpone L-dopa 
introduction and its associated dyskinesia [52]. Furthermore, due to the fact that this 
class of compounds can delay the onset of dyskinesias and motor fluctuations, by one 
to three years, after L-dopa introduction  DA agonist are also used as adjuvants to L-
dopa in the later stages of the disease [53] .  
The main advantage associated with the use of dopamine agonists is the fact 
that they can act directly on dopamine receptors, bypassing the metabolic pathways in 
the degenerated nigrostriatal neurons [54-56]. It was also postulated that the 
antioxidant/free radical-scavenging activity demonstrated by this type of compounds, 
makes them good candidates for neuroprotection of the dopaminergic and non-
Benserazide
Carbidopa
Figure 2.5 Chemical structures of L-
AAD inhibitors. 
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dopaminergic neurons [56-59]. These additional effects, although very important to the 
management of PD, still remain unproven and may not be significant for clinical 
practice as suggested for some authors [60, 61].  
DA agonists are a heterogeneous group of drugs classically divided into ergot or 
non-ergot agonists. The ergot DA agonists (Fig. 2.6) are based on the structure of 
ergoline and include: bromocriptine, cabergoline, lisuride, and pergolide. The non-ergot 
DA agonists (Fig. 2.6) are a more diverse chemical group comprising apomorphine, 
piribedil, ropinirole, pramipexole, and rotigotine [54]. Due to several side effects, such as 
impulse control disorders (e.g. pathological gambling, hyper sexuality, or binge eating) 
the treatment with dopamine agonists must be initiated at low dosage and the titration 
period may be extended for months in order to improve tolerance to the peripheral side 
effects [62]. This dose escalation process may have direct implications in the patient´s 
compliance to the treatment due to the time needed for beneficial effects to manifest.  
 
 
Figure 2.6 Chemical structures of ergot and non-ergot dopamine agonists. 
 
2.3.1.3 Catechol-O-methyltransferase inhibitors 
Catechol-O-methyltransferase (COMT) is an intracellular enzyme widely 
distributed in human tissues and highly active in liver, kidneys and gastrointestinal tract 
Apomorphine Piribedil Ropinirole Pramipexole Rotigotine
Bromocriptine PergolideCabergolineLisuride
Ergot Derivatives
Non-ergot Derivatives
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[63]. This enzyme in presence of Mg2+ promotes the O-methylation of one of the hydroxyl 
groups present on the catechol substrate [63]. 
To understand the role of COMT inhibitors, as a valid resource for PD, it is 
important to highlight the role of this enzyme in the peripheral metabolism of L-dopa. 
Besides the peripheral conversion of L-dopa to dopamine via L-AAD, L-dopa is also 
peripherally metabolized to its inactive metabolite 3-O-methyldopa (3-OMD) (Fig. 2.7), 
by the action of COMT [63, 64]. The use of COMT inhibitors allows a prolonged 
maintenance of L-dopa serum levels, by increasing its half-tlife and boosting the central 
bioavailability of the drug. These drugs have the additional advantage of low motor 
fluctuations and less dependence on daily L-dopa [64].  
 
 
There are two COMT inhibitors, available since the mid-1990s, for clinical 
practice: tolcapone and entacapone (Fig. 2.8) [65]. Entacapone is a selective and 
reversible peripheral COMT inhibitor that does not cross the blood brain barrier (BBB) 
acting primarily in the increase and maintenance of plasmatic half-life of L-dopa [66]. 
Tolcapone has a half-life similar to entacapone but, as it has a greater bioavailability 
and smaller volume of distribution, thus resulting in higher potency for COMT  
inhibition [54]. Furthermore, tolcapone, unlike entacapone, may also inhibit central 
COMT brain [67, 68], increasing peripherally and central L-dopa availability, thus 
enhancing striatum dopamine neurotransmission [68]. However, the appearance of fatal 
acute hepatitis in some patients receiving tolcapone, raised several concerns about this 
3-OMD L-Dopa
COMT
L-Dopa
L-Dopa
Liver
Kidneys
GI tract
 Figure 2.7 Peripheral biotransformation of L-dopa by action of COMT. COMT: Catechol-O-methyltransferase and 
3-OMD: 3-O-methyldopa. 
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drug and the European Medicines Agency (EMEA) has temporary suspended 
tolcapone in the European Union (EU) [67, 69]. In 2004, EMEA lift the suspension but  its 
use was substantially curtailed [67]. Comparatively, entacapone does not show the 
same tendency to cause hepatotoxicity, being the most common side effects related 
with the dopaminergic system. As reflex of the increased central dopaminergic activity, 
nausea, vomiting, orthostatic hypotension, and dyskinesia, can be experienced by the 
patients undergoing COMT inhibitors therapy. Additionally, it was reported the 
occurrence of diarrhoea in about 10% of cases, and in some patients it may be 
intractable and discontinuation of the drug may be required [70].  
Recently, a novel catechol-O-methyltransferase (COMT) inhibitor, opicapone 
(Fig.2.8), was developed by BIAL and has been proposed as adjunctive therapy for PD 
patients treated with L-dopa. Opicapone is currently in phase III clinical trials and a 
license agreement was signed with Ono Pharmaceutical Co., Ltd. (―ONO‖) for the 
development and commercialization in Japan [71]. 
 
 
 
Figure 2.8 Chemical structures of COMT inhibitors. 
 
 
 
 
 
Tolcapone Entacapone Opicapone
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2.3.1.4 Monoamine oxidase-B inhibitors  
Monoamine oxidases 
(MAOs) are intracellular 
flavine-containing enzymes 
that play a major role in the in 
vivo inactivation of biogenic 
amines, both in peripheral and 
central neuronal tissues [72]. 
These enzymes are 
ubiquitously distributed on the 
body and are mainly located 
in the outer mitochondrial 
membrane. The biological role 
of MAOs is the catalysis of the 
oxidative deamination of 
endogenous monoamines 
(Fig. 2.9) by a process that 
involves the oxidation of the 
amine function, with the 
formation of an imine 
intermediate and 
simultaneous reduction of the 
flavin cofactor. The imine 
intermediate is then hydrolysed, yielding ammonia and the corresponding aldehyde. 
The cofactor is re-oxidized by molecular oxygen, with concomitant hydrogen peroxide 
release (Fig. 2.9) [73]. 
Two isoforms of MAOs are expressed in mammals: MAO-A and MAO-B, which 
can be distinguished based on their substrate preference for the substrate and their 
interaction with specific inhibitors [73, 74]. Within the CNS, the primary substrates of MAO 
are neurotransmitters, such as adrenaline, noradrenaline (NA), dopamine (DA), 
serotonin, also called 5-hydroxytryptamine (5-HT), and β-phenylethylamine (PEA). 
However, a variety of monoamines, like tyramine, octopamine, tryptamine and 
kynuramine, can be also metabolised by MAO. These substrates are deaminated by 
both isoforms of the enzyme, albeit with differing kinetic parameters, which are 
influenced by concentration, affinity and turnover rate of the substrate. Under normal 
physiologic conditions, NA and 5-HT are the preferred substrates of MAO-A, and PEA 
FAD + H2O+O2 FAD + H2O2 + NH3
Figure 2.9 MAOs catalysed reactions 
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is preferentially metabolised by MAO-B. Both MAOs isoforms metabolise DA, although 
DA in human brain has higher affinity for MAO-B isoform [75].  
These findings led to the development of selective inhibitors for each subtype of 
MAO, being MAO-A a target in the treatment of depression, whereas MAO-B inhibitors 
are used in therapy for neurodegenerative disorders, including PD [74]. MAO-B inhibition 
causes the blockade of the metabolism of dopamine and therefore could enhance both 
endogenous dopamine and the one produced from exogenously administered L-dopa.  
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a chemical compound, 
which was linked with parkinsonism by serendipity, had a significant impact on PD 
research and it was used since then as a tool to investigate the cause and treatment of 
the disease namely in the development of suitable PD animal models [76]. The 
neurotoxic effects are not caused by MPTP by itself, but by its bioactive metabolite, the 
1-methyl-4-phenylpyridinium ion (MPP+), a metabolic process which can be MAO-B 
mediated. The active metabolite exerts is toxicity by acting as mitochondrial complex I 
inhibitor inducing cell death [77]. There are several studies suggesting that MAO-B 
inhibitors can block the conversion of MPTP to its active metabolite MPP+, thus giving 
rise to the thought that they can possess some neuroprotective properties [75, 78].  
The MAO-B inhibitors currently in the market, selegiline (L-deprenyl) and 
rasagiline (Fig. 2.10) are both selective and irreversible inhibitors of MAO-B isoform. 
Selegiline in combination with L-dopa presents very successful results in the treatment 
of PD. First synthesised in 1962, the low potential of selegiline to produce the so-called 
"cheese effect", a common reaction following the usage of MAO inhibitors, had 
attracted attention even before MAO subtypes have been discovered. Additionally, 
selegiline may also display neuroprotective 
properties through the decrease of oxidative stress 
in neuronal striatal circuit [79]. A negative feature of 
selegiline is related to its biotransformation in 
amphetamine-like metabolites; two of them, L-
amphetamine and L-methamphetamine, have 
shown to be potential neurotoxins. Despite the fact 
that the neurotoxicity mechanisms are not 
completely understood, it has been proposed that it 
involves damage in dopaminergic and serotonergic 
cells [80-82]. 
Rasagiline (Fig. 2.10) is a potent, selective and irreversible inhibitor of MAO-B. 
One of its main therapeutic advantages is related to its biotransformation, as no 
amphetamine-like metabolites are obtained [82-84]. Moreover, its major metabolite ((R)-1-
Seligiline
Rasagiline
Figure 2.10 Chemical structures of MAO-
B inhibitors in clinical practice  
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aminoindan) exhibits neuroprotective activity in animal PD models [85]. Studies with 
patients, with moderate to severe symptoms of PD treated with L-dopa, showed that 
rasagiline improves the typical symptoms and motor fluctuations [86]. The key to the 
success of rasagiline seems to be its ability to limit the process of neurodegeneration in 
the early stages of the disease [87].  
The multitarget drug discovery approach recently proposed for multifactorial 
diseases has already brought out encouraging results regarding PD. The development 
of new chemical entities (NCEs) with a MAO-B inhibitory activity allied to another 
relevant mechanism of action, culminated in synthesis of two new compounds: 
ladostigil and safinamide (Fig. 2.11).  
The identification of the propargylamine 
moiety as a key structure related with the 
neuroprotective activity of MAO-B inhibitors was 
the inspiration for the design and development of 
ladostigil [10]. Ladostigil, is a NCE that combines 
the neuroprotective effects of the propargylamine 
moiety, the MAO-B inhibition profile of rasagiline 
and retains the acetylcholinesterase (AChE) 
inhibitory activity of rivastigmine [88]. 
Safinamide is an aminoamide derivative, 
currently in Phase III clinical trial for Parkinson´s 
disease, which has been shown to be a reversible 
MAO-B inhibitor with the capacity to reduce dopamine reuptake and with 
antiglutamatergic effects. This NCE may add a new dimension to PD treatment options, 
either as an adjuvant to current drugs for neuroprotection or motor symptomatic relief in 
PD, as it displays dopaminergic and non-dopaminergic effects [89].  
2.3.2 Non-dopaminergic treatments for Parkinson´s disease  
2.3.2.1 Anticholinergic drugs 
Before the discovery of L-dopa the therapy of choice for PD relied on 
anticholinergic drugs. The first‘s reports involving the use of anticholinergic drugs for 
ameliorating the motor symptoms of PD remount to the nineteen century (late 1860‘s, 
early 1870‘s) with use of the belladonna alkaloids, atropine and scopolamine. The 
synthetic anticholinergic agents, namely, trihexyphenidyl, Biperiden, procyclidine, 
benzatropine and ethopropazine were only marketed for the treatment of PD in  
1950‘s [90-92] (Fig. 2.12). Although the benefits were modest and inconsistent, 
Ladostigil
Safinamide
Figure 2.11 Chemical Structures of 
multitarget drugs in clinical trials. 
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anticholinergic drugs remained the cornerstone of PD therapy for nearly one hundred 
years.  
The rational use of anticholinergic 
agents in PD has been strengthened by 
the clear demonstration of 
dopaminergic-cholinergic antagonism in 
the striatal function [55]. The mechanism 
of action of the anticholinergic drugs in 
PD is not yet thoroughly known, but it is 
postulated that these drugs can 
antagonise overactive cholinergic 
transmission via blockade of 
postsynaptic muscarinic receptors, 
thereby restoring the balance between 
DA and ACh in the  
striatum [55, 93]. Although anticholinergics 
may be useful as monotherapy in early 
stages of PD, they are mainly used as 
adjuvants to L-dopa treatment. They are 
more effective in ameliorating the mild 
symptoms of tremor and rigidity, without 
significant changes in bradykinesia signals [94]. Anticholinergic agents can also block 
muscarinic ACh receptors peripherally leading to a myriad of side effects like 
xerostomia, sweating inhibition, blurred vision, and urinary retention as the most 
common ones. CNS side effects, such as confusion, dementia and other psychiatric 
symptoms are also  
frequent [95].  
2.3.2.2 Glutamate antagonists 
Amantadine (Fig. 2.13) is a tricyclic amine that was 
firstly used as an antiviral agent. Its benefits in PD therapy 
were discovered by serendipity in 1969 by Schwab et al. [96]. 
Despite the lack of scientific evidence of its efficacy 
regarding the delay of  PD progression, this drug has been 
used for the relief of PD motor since then [55]. Amantadine is 
administered either in combination with L-dopa or in monotherapy, in patients that have 
less tolerance for L-dopa [97]. More recently, the interest on this drug has re-emerged 
Figure 2.13 Chemical 
structure of amantadine. 
Trihexyphenidyl
Biperiden
Procyclidine
Benzatropine
Ethopropazine
Figure 2.12 Chemical structures of anticholinergic 
drugs 
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due to its putative beneficial role in the treatment of motor fluctuations and  
dyskinesias [98, 99]. The exact mechanism of action of amantadine remains unclear. The 
role of this drug in PD has been related to the antagonism exerted on N-methyl-D-
aspartate (NMDA) receptor subtype, but other mechanisms have also been proposed, 
such as direct action over the dopaminergic system. None of the mechanisms so far 
proposed met the rigorous criteria for strength of evidence [55,100, 101]. 
However, the use of amantadine in therapy is limited due to its side effects, which 
are generally mild but may be severe, especially in elderly patients, and also due to the 
discovery of more effective therapeutic approaches. Adverse effects associated with 
amantadine usage are primarily central nervous system ones, like anxiety, 
hallucinations, depression, insomnia, somnolence/drowsiness, fatigue and impaired 
coordination, along with non-SNC effects, such as diarrhoea, nausea and vomiting, 
constipation, xerostomia, and livedo reticularis [98].  
2.4 Looking for new targets: adenosine A2A receptors and 
Parkinson´s disease 
To date, most of the currently available therapies in PD target the dopaminergic 
system and none of these therapeutic approaches have been proven to modify the 
course of the disease. To various extents, these drugs can also cause motor and non-
motor complications [102]. 
The need for potent and safe antiparkisonian agents has been the motor of an 
intensive research towards the development of new therapeutic approaches for PD, 
preferentially one that can operate beyond the damaged dopaminergic system. In fact, 
in the last years a large number of medicinal chemistry programs have been focused in 
looking for new non-dopaminergic modulators of basal ganglia motor circuits [103]. 
As mentioned previously in section 2.3.2, there are available medicines whose 
mechanisms of action operate via a non-dopaminergic pharmacological approach (e.g. 
anticholinergic drugs and amantadine) illustrating the viability and the problems of this 
type of therapeutic strategy for PD motor symptoms relief [104]. So, the development of 
novel antiparkinsonian agents whose mechanisms of action are mediated by other 
specific CNS receptors, preferentially restricted to basal ganglia neurons, may have an 
intrinsic therapeutic advantages while reducing the occurrence of adverse CNS events.  
2.4.1 G Protein-coupled receptors and adenosine receptors: a general 
outlook 
Adenosine can act as neuromodulator and has been associated with the 
coordination responses to DA and other neurotransmitters, in areas of the brain that 
are responsible for motor function, mood, learning and memory [105, 106]. The 
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physiological functions of adenosine are mediated by adenosine receptors (ARs). 
Briefly, these receptors are G protein-coupled receptors (GPCRs) consisting of a single 
polypeptide chain that transverses the membrane from the extracellular side, beginning 
at the N terminus, to form seven transmembranar helices (TMs), which are connected 
by three intracellular and three extracellular loops (ILs and ELs, respectively), leaving 
the N-terminus in the extracellular milieu and the C-terminus in the cytoplasm [107] (Fig.  
2.14). 
There are four distinct ARs subtypes designated as A1, A2A, A2B and A3. 
Adenosine A1 and A3 receptors are coupled to inhibitory G proteins, while A2A and A2B 
receptors are coupled to stimulatory G proteins. The A2A and A2B ARs preferably 
interact with members of the Gs family of G proteins, with consequent activation of 
adenylyl cyclase and consequently the production of cyclic AMP (cAMP), and 
contrariwise, the A1 and A3 ARs inhibit the adenylyl cyclase activity by interaction with 
Gi proteins 
[107] (Fig. 2.14). 
 
 
Figure 2.14 Schematic representation of G protein-coupled adenosine receptors. ATP: Adenosine-triphosphate; 
Ca
2+
: ion Calcium (II); cAMP: Cyclic adenosine monophosphate; Gi/Go: inhibitory G protein; Gs/Gq stimulatory G 
protein; K: potassium; P: phosphorus; PLC: phospholipase C. 
 
GPCRs have been implicated in a multitude of human disorders and numerous 
diseases as their signalling regulates an incredibly vast array of physiological functions 
and pathological conditions. Consequently, they have a high pharmaceutical appeal 
and constitute the target of a very large segment of the currently marketed drugs [108]. It 
is estimated that nearly half of all modern drugs somehow regulate GPCR activity [109].  
Although GPCRs are among the most fruitful targets for marketed drugs, and 
while intense discovery efforts have been performed to find agents for GPCR subtypes, 
a selective drug candidate has not yet been reported. Particularly, ARs have long been 
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considered as targets for drug discovery programs of a variety of maladies, such as 
cerebral and cardiac ischaemia, immune and inflammatory disorders, and more 
recently for neurodegenerative and neoplastic events [108, 110, 111]. Consequently, 
numerous medicinal chemistry groups have made intense efforts to create selective 
agonists and antagonists for each AR subtype [112-115].  
2.4.2 Adenosine, adenosine receptors and neurodegenerative diseases 
Adenosine is a neuromodulator with several functions in the CNS, such as 
inhibition of neuronal activity in many signalling pathways [105,106,116,117]. Adenosine plays 
a major role in a diverse array of neural phenomena, which includes regulation of sleep 
and the level of arousal, neuroprotection, seizure susceptibility, locomotor effects, 
neuroprotection and modulation of various neurotransmitters, namely dopamine. The 
existence of an interaction between adenosine and dopamine within the basal ganglia, 
which could be correlated with the modulation of motor function, has been 
demonstrated [105, 116, 117]. Adenosine can also counteract the excitotoxicity associated 
with excessive glutamate release in the brain [118]. The overall findings support the 
hypothesis that adenosine plays an important role in the modulation of glutamatergic 
and GABAergic neurotransmission [28, 119, 120] of the basal ganglia indirect pathway [121].  
The neuromodulation effect exerted by adenosine occurs probably through the 
activation of the A1 and A2A ARs, which are highly expressed in brain 
[122]. The A2A AR 
in the CNS, distinguishes itself from the other adenosine receptors by its selective 
localization in striatum [107] (Fig. 2.15). In the striatum the A2A AR are co-localize and 
physically associated with DA D2 receptors. A2A AR and D2 receptors have opposing 
effects on adenylyl cyclase and cAMP production in cells. Interestingly, A2A AR 
activation reduces the affinity of striatal D2 receptor for dopamine and the blockade of 
A2A AR with specific antagonists facilitates function of the D2 receptor. Blockade of A2A 
AR signalling by selective A2A AR receptor antagonists was shown to be beneficial not 
only by enhancing the therapeutic effects of L-Dopa but also by reducing dyskinesia 
from long-term L-Dopa treatment.  
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The specific 
localization of A2A ARs 
at basal ganglia, their 
biochemical and  
pharmacological 
properties, advocate 
that they will be 
effective targets in  
PD [120]. Therefore, 
A2A AR antagonists 
will potentially reduce 
the effects associated 
with dopamine depletion in PD. In fact this class of compounds have recently attracted 
considerable attention as they have shown potential effectiveness in counteracting 
motor dysfunctions, while displaying additional neuroprotective and anti-inflammatory 
effects in animal models of PD [60, 117, 118]. They have distinguished themselves over 
other antiparkinsonian agents in development, by the convergent epidemiological and 
preclinical evidence of their neuroprotective benefits as well as symptomatic  
relief [117, 118]. 
2.4.2.1 A2A AR antagonists 
The knowledge acquired over the last decades regarding the involvement of 
adenosine on motor functions, mainly 
through modulation of A2A receptor, makes 
A2A AR antagonists promising non-
dopaminergic agents for the treatment of PD 
motor symptoms. A2A AR antagonists 
developed do far have been traditionally 
categorized as xanthine based (e.g. caffeine 
and styrylxanthines) or non-xanthine based 
derivatives (e.g. pyrazolotriazolo pyrimidines, 
arylindeno pyrimidines, thiazolotriazolo 
pyrimidines). Excellent reviews have been 
published on this topic in the last five 
years[123-126].  However, until now only two 
A2A AR antagonists have undergone clinical 
evaluation, namely, istradefylline (KW-6002) and preladenant (SCH 420814) (Fig. 
Figure 2.15 Co-localization of A2A AR and D2 receptors 
Istradefylline
Preladenant
Figure 2.16 Chemical structures of istradefylline 
and preladenant. 
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2.16). The preclinical data demonstrates that istradefylline possesses beneficial effects 
on PD symptoms, and in clinical trials it has shown the ability to reduce the ―off‖ time in 
patients with PD receiving dopaminergic therapy [117]. Istradefylline completed phase III 
clinical trials in 2009, but it was not approved by the FDA due to lack of efficacy in 
comparison with placebo [127]. Preladenant was being researched as a potential 
treatment for Parkinson's disease. Although positive results were reported in Phase II 
clinical trials it did not prove itself to be more effective than a placebo during Phase III 
trials, and so it was discontinued in May 2013. 
2.5 Chromone as a privileged scaffold  
2.5.1 Privileged structures for lead discovery  
The term privileged structure was first introduced in 1988 by Evans and co-
workers[128] who have recognised the potential of certain regularly occurring structural 
motifs as templates for structural modification to expand the discovery of novel ligands 
for binding to proteins. Since then, the original concept definition has evolved and 
nowadays privileged structures (scaffolds or motifs) can be defined as molecular 
frameworks which are able of providing useful ligands for more than one type of 
receptor or enzyme targets by judicious structural modifications[129]. Privileged 
structures typically exhibit drug-like properties and usually generate drug-like 
compound libraries and lead compounds. However, one should keep in mind that the 
presence of a privileged scaffold in a compound is no guarantee that all compounds in 
the library will be bioavailable and non-toxic.  
Many of these frameworks have been used as templates for the design of 
libraries of molecules for drug discovery [130-134]. In fact, the privileged structure concept 
has emerged as a successful approach for the drug discovery process, e.g. as core 
structures for synthesis and optimal starting points for the library design of ligands with 
affinity to certain molecular targets [130-134]. The last decade has brought more popularity 
to this idea and numerous scaffolds have been claimed to be privileged: 
benzazepinone, diphenylmethane, piperidine, biphenyltetrazole, indole, biphenyl and 
benzopyrane [13, 130]. However, the prerequisites that make a structural motif a 
privileged one still remain unknown. Nevertheless, it is consensual that there are at 
least two important issues that can make a privileged structure suitable for fragment-
based design: synthetic availability and ease of modifying its structure. The decoration 
of the privileged scaffolds using diversity-oriented synthesis has been proven to be an 
essential tool to rapidly discover biologically active small molecules. During the design 
of a synthetic library, it is advised to exploit simple one-pot approaches, e.g. 
condensation reactions that afford high yields. On the other hand, for building the 
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structure-activity matrix, usually guided by (bio)isosteric approaches, the tested 
compounds should be relatively versatile and cover a wide range of substituents [135]. 
Privileged substructures from bioactive natural products are usually rigid 
heterocyclic based structures and have played and continue to play an invaluable role 
in the drug discovery process[12]. In particular, benzopyrane is a privileged structural 
motif observed in many biologically active natural products that has been extensively 
studied by several research groups[136], especially using as templates coumarin (2H-
chromen-2-one) and flavonoid (2-phenyl-4H-chrome-4-one) or isoflavonoids (3-phenyl-
4H-chrome-4-one) structure based scaffolds.  
Although chromone has not been included so far as a benzopyrane privileged 
scaffold it is our believe that due to the number of natural chromone derivatives, the 
high degree of chemical diversity linked to the broad spectrum of pharmacological 
activities, they can be an important player in the medicinal chemistry drug discovery 
and development programs.  
2.5.2 Simple chromones 
Chromones are a group of naturally benzopyrone compounds that are ubiquitous 
in nature, especially in plants. Chromones are oxygen-containing heterocyclic 
compounds with a benzoannelated γ-pyrone ring (4H-chromen-4-one, 4H-1-
benzopyran-4-one). Due to their structural diversity they are roughly divided into two 
different categories: simple chromone derivatives and 
fused chromones such as pyrano and 
furanochromones. 
Simple chromones are a vast group of 
heterocyclic compounds of great biological and 
synthetic interest being (iso)flavonoids the most studied 
components of this group. Up till now, simple 
chromones have been progressively explored and, with 
the exception of (iso)flavonoids, and the literature in this 
area is rather diffuse. However, this type of compounds 
has attracted interest for a long time either from a 
biosynthetic and synthetic point of view and/or due to 
their interesting biological activities. In the present study our attention was focused on 
simple chromones, which do not have the characteristic B ring of the (iso)flavonoids 
(Fig. 2.17).  
A C B
A C
Chromone backbone
(Iso)flavonoids backbone
Figure 2.17 Chromone and 
(iso)flavonoids backbone. 
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2.5.3 Chromones in therapy 
Chromones have been used in therapy since ancient times. One of the most 
charismatic examples of natural chromones in clinical practice is khellin (Fig. 2.18), a 
furanochromone, extracted from the seeds of the plant Ammi visnaga. Historically, 
khellin and its 9-demethoxy derivative, visnagin, were employed as herbal medicines in 
the treatment of angina, spasmolytic agents, and were also used for kidney stone 
treatment [137], but the first clinical application of khellin in its pure form was as 
bronchodilator in asthma [138, 139]. However, due to the unpleasant side effects (nausea 
and vomiting) the use of khellin for asthma events was abandoned [138, 139]. Currently 
khellin is still used as a therapeutic agent in the treatment of vitiligo [140].  
The search for NCEs based on khellin with bronchodilation properties, without the 
inherent side effects and with a better water-solubility profile, led to the synthesis of a 
small molecule, the chromone-2-carboxylic acid (Fig. 2.18). This chromone was able to 
prevent bronchial spasms caused by antigens [138] but unfortunately the effect was too 
short lived to be clinically useful [141]. Further research has culminated in the 
development of the so-called bis-chromones, namely disodium cromoglycate (Fig. 
2.18) a chromone that was largely employed for the treatment of bronchial asthma. 
Although nowadays the therapy for asthma relied on corticosteroids, sodium 
cromoglycate is still useful in the treatment of mild to moderate asthma, especially in 
children, mainly due to its lower risk profile compared to the inhaled corticosteroids and 
to its potent anti-inflammatory effect [142].  
 
 
Figure 2.18 Examples of chromone derivatives in therapy 
2.5.4 Biological activity of simple chromones and derivatives 
Numerous biological activities have been attributed to simple chromones and 
their analogues, such as anticoagulants and antiplatelet [143-146] as well as 
antidiabetics[147] activities. Their ability to act as inhibitors of carbonic anhydrase [148, 149], 
NADH:ubiquinonereductase (complex I) [150, 151] and calpain [152, 153] was also reported. 
However, in this work only the most illustrative properties, namely anti-inflammatory, 
antimicrobial, anticancer and those related with neurodegenerative diseases, will be 
further discussed.  
Khellin chromone-2-carboxylic acid disodium cromoglycate
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The following subdivisions intend to summarise the developed medicinal 
chemistry artwork related with the potential therapeutic applications of simple 
chromones and their derivatives, with the exception of flavonoids. 
2.5.4.1 Anti-inflammatory activity  
The current mainstay treatment of inflammatory diseases, namely those related 
with rheumatoid (arthritis), respiratory (asthma), cutaneous (psoriasis) and irritable 
bowel syndrome (IBS) disorders, involve the use of corticosteroids and non-steroidal 
anti-inflammatory drugs (NSAIDs). However, both therapeutic approaches are linked 
with several side effects mainly related to a lack of drug target selectivity, among others 
factors. Despite some notable successes in the field, there is still a major unmet 
medical need for the treatment of inflammatory diseases. In addition, it has become 
clear over the last few years that inflammatory processes may also play a key role in 
other prevalent diseases, not previously considered to have inflammatory aetiologies, 
such as atherosclerosis, diabetes, cardiovascular, Alzheimer's and Parkinson's 
diseases as well as cancer.  
Over the past 20 years in the modern era of target-based drug discovery, a 
relatively small number of pivotal targets have been identified and linked to 
inflammatory process. Most of these are antagonists of endogenous pro-inflammatory 
mediators, such as prostaglandins, leukotrienes (LTs) and histamine, exerting their 
biological role by interacting with enzymes, such cyclooxygenases 1 and 2 (COX-1 and 
COX-2 respectively) and with LT receptors. In this context, several studies aiming at 
the discovery and development of novel anti-inflammatory agents based on chromone 
scaffold were performed. Accordingly, 7-methanesulfonylamino-6-phenoxychromone 
(Fig. 2.19) and analogues were synthesised and evaluated for acute and chronic 
inflammation  [154]. From the data a 3-
formylamino derivative (T-614) (Fig. 
2.19), has emerged as a prospective 
disease-modifying antirheumatic agent. 
Inspired by stellatin (Fig. 2.20), a natural 
chromone isolated from Dysophylla 
stellatais described as a cyclooxygenase 
inhibitor, Gautam et al.  synthesised and 
evaluated several  stellatin derivatives 
towards COX-1 and COX-2 [155].  
(1) R=H
(2) R=NHCHO
Figure 2.19 Chemical structures of (1): 7-
methanesulfonylamino-6-phenoxychromone and (2): 
T-614. 
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From the SAR studies it is 
possible to highlight the compounds 
represented in Fig. 2.20. Compound 1 
and 2 (Fig. 2.20) exhibited the highest 
COX-2 inhibitory activity off all the 
tested compounds and a significant anti-
inflammatory outline in a TPA-induced 
mouse ear edema model. Furthermore,  
compounds 1 and 3 (Fig. 2.20) exhibited 
higher anti-inflammatory activity than 
indomethacin [155].  
In the 1980s and 1990s the discovery and development of novel LT receptor 
inhibitors based on the chromone nucleus 
prompted the emergence of pranlukast (Fig. 
2.21). This drug was initially launched in the 
market for the management of asthma and 
in 2000 its license was extended for its use 
in allergic rhinitis. It is also worthy to 
mention, the discovery of one of the most 
potent leukotriene D4 (LTD4) antagonists so 
far reported RG 12553 (Fig. 2.21). RG 
12553 was designed based on the 
combination of pranlukast and FPL 55712, a 
cromoglycate derivative previously 
described as LTD4 antagonist [156] (Fig. 
2.21).  
Additionally, the (piperidinylalkoxy) 
chromone derivatives (Fig. 2.22) have been 
also described as an important motif for the 
development of antihistaminic compounds with additional antagonistic activity against 
LTD4 [157].  
 
 
Stellatin
(1) R1= OH; R2=OH
(2) R1= OH; R2=OCH3
(3) R1= R2=isoC4H9
Figure 2.20 Chemical structures of stellatin and its 
derivatives. 
Pranlukast
FPL 55712
RG 12553
Figure 2.21 Chemical structures of pranlukast, 
FPL 55712 and RG 12553. 
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Figure 2.22 LT receptor antagonists based on (Piperidinylalkoxy)chromone scaffold. 
 
Chromone derivatives were also described as potential anti-asthmatic and anti-
allergic compounds by targeting mast cells and preventing the release of anaphylactic 
substances, such as the slow-reacting substance of anaphylaxis (SRS-A) [158], or 
stopping the allergic responses triggered by them, by the inhibition of the passive 
cutaneous anaphylactic (PCA) reaction [159-169].  
2.5.4.2 Antimicrobial activity 
Over the past 70 years, antimicrobial drugs, such as antibacterial, antifungal and 
antiviral agents, have been successfully used to treat patients with infectious diseases. 
Over the course of time, however, many infectious organisms have adapted to the 
available chemotherapy and the existing drugs became progressively less effective. 
The emergence of multidrug resistance in common pathogens and the rapid 
emergence of new infections are the main reasons to drive the discovery and 
development of new antimicrobial compounds forward. Some of the medicinal artwork 
in this particular field was based on the chromone structure. Several chromone 
derivatives, either of synthetic or natural origin, have been recognized to display 
valuable antibacterial and antifungal activity [170-173]. The usefully of the chromone 
nucleus as starting point to develop NCEs with potential antimicrobial activity is well 
demonstrated in the work of Chohan et. al. [174].  In this work several sulfonamide 
derived chromones were synthesised and their antibacterial activity evaluated against 
several Gram-negative (Escherichia coli, Pseudomonas aeruginosa, Salmonella typhi 
and Shigella flexeneri) and Gram-positive (Bacillus subtilis and Staphylococcus aureus) 
bacteria. Additionally, the same compounds were evaluated towards its antifungal 
activity against different fungi: Trichophyton longifusus, Candida albicans, Candida 
glaberata, Aspergillus flavus, Microsporum canis, Fusarium solani. From this work,  the 
chromone derivative represented in Fig.2.23 A arises as the most promising compound 
of the tested library [174]. Other interesting chromone derivative with antimicrobial 
activity is the dithiazole represented in Fig. 2.23 B. This compound exhibited a better 
antifungal activity against Geotrichum candidum when compared to fluconazole and 
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also showed a significant antibacterial activity against  
Shigella flexneri [175].  
 
 
Figure 2.23 Chemical structures of A: sulfonamide chromone derivative and B: Dithiazole chromone derivative. 
 
Others classes of chromone-based compounds, such as pyrazolylidene, 
imidazolydene and pyrimidinyliden [176], glucosides and aglycones [177]  as well as fused 
nitrogen heterocyclic systems [178] and  Chitosan derivatives [179],  have also been tested 
as putative antimicrobial agents, revealing themselves as promising lead compounds to 
further development in the area. 
As an example of chromone derivatives with potential antiviral activity, it is 
possible to highlight the 2-styrylchromones shown in Fig. 2.24 A[180, 181]. Furthermore, 
the (E)-5-hydroxy-2-styrylchromone and (E)-4'-methoxy-2-styrylchromone showed 
activity against human noroviruses. This study led the authors to propose the (E)-2-
styrylchromone scaffold as a lead compound, for further development of  new antiviral 
drugs [182]. 5-Hydroxy chromones, like the one represented in Fig. 2.24 B, were also 
proposed as an interesting scaffold for 
the development of anti-hepatitis C 
virus drugs [183]. The chromone moiety 
was also proposed as a putative 
scaffold for the development of NCEs 
against the human immunodeficiency 
virus (HIV), mainly due to their 
capacity to inhibit the reverse 
transcriptase [184-186] and integrase-
mediated strand transfer [187] enzymes. 
2.5.4.3 Anticancer activity  
The chromone backbone has also been used to discover and develop NCEs with 
anticancer potential. Accordingly, a number of chromone derivatives were screened 
toward a panel of cancer cell lines [188-195]. Some of the obtained results are herein 
highlighted: i) Substituted-3-(5-phenyl-3H[1,2,4]dithia-zol-3-yl)chromones and 
A B
R=H/OH/OCH3
A B
Figure 2.24 Chromone derivatives with antiviral activity. A) 
2-styrylchromones; B) 5-hydroxy chromone scaffold. 
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substituted chromones with a N-
phenylthioamide in position-3 (Fig. 2.25 A) 
have shown significant cytotoxic activity 
[196]; ii) Heterocyclic-substituted chromone 
derivatives have been screened and 6-
chloro-2-(2-quinolyl) chromone (Fig. 2.25 
B) emerged as the most promising 
compound,  due to its significant activity 
towards Sarcoma 180 [197]. iii) Several 
chromone phosphorus hydrazides 
derivatives (Fig. 2.25 C) have been 
reported as having antineoplastic activity 
against P388 and L1210 leukemia either in 
monotherapy or in combination with 
methotrexate [190, 198, 199].  
Other works reported several chromone derivatives as potential inhibitors of 
enzymes implied on tumour growth, namely kinases [200-203], protein tyrosine 
phosphatases [204], thymidine phosphorylase (TP) [198], topoisomerases [205] and 
aromatase [206]. 
A series of 2-styrylchromone analogs (Fig. 2.26) were synthesised and examined 
for their antiproliferative effects on a panel of carcinoma cells, showing the ability to 
induce cell death through sub-G1 arrest and DNA 
fragmentation, demonstrating the putative implication 
on the molecular mechanisms of apoptosis 
(compound A, Fig. 2.26) [192]. Other studies 
performed with compound B (Fig. 2.26) proved that 
its capacity to promote cell death can probably result 
from the induction of procaspases and other 
apoptotic enzymes and by a strong decrease of the 
available ATP [207]. Moreover, inhibitors of poly(ADP-
ribose) synthetase and mono(ADP-ribosyl) 
transferase  with a chromone core were also studied 
due to their role in cell death [208]. 
 
A
B
C
Figure 2.25 Chromone scaffolds for the development 
of NCE with anticancer activity. 
A
B
Figure 2.26 2-styrylchromones with 
antiproliferative activity on a panel of 
carcinoma cells. 
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2.5.4.4 Drugs for neurodegenerative diseases 
Neurodegenerative diseases such as AD, PD and Huntington's diseases, among 
others, have in common a neurophatological feature of progressive loss of brain 
neurons and related functions, with direct consequences on the levels of 
neurotransmitters. AD and PD are among the two most prevalent neurodegenerative 
diseases worldwide and their aetiology remains unclear. However, over the last 
decades it became clear that AD is classically characterized by a loss of basal 
forebrain cholinergic cells, whereas the most prominent histopathological feature of PD 
is the loss of dopaminergic neurons and consequent imbalance of ACh and DA 
neurotransmitters.  
Accordingly, increasing the levels in ACh has been regarded as one of the most 
promising approaches for the symptomatic treatment of AD [88]. It was also recently 
demonstrated that acethylcolinesterase (AChE), an enzyme responsible for the ACh 
metabolism, could also play a key role in accelerating β-amiloid (Aβ) plaques 
deposition, an important factor observed on patients with AD [88]. Furthermore and 
although the mechanism of action is not yet completely understood, as mentioned 
previously in section 2.2, ACh through its receptors seems to be implied in the 
regulation of the dopamine in striatum, and by that correlated with the symptomatic 
treatment in PD. In fact, anticholinergic drugs are among the oldest drugs used to treat 
PD [55, 93]. Other neurotransmitter that can be correlated with both of the diseases is DA. 
In fact, and despite the important role of DA in PD (previously mentioned in this work), 
it was recently evidenced that DA might be involved in cognitive dysfunction occurring 
in AD, mainly due to the strong synaptic interactions with ACh, in different brain  
areas [209, 210].  
The application of the chromone backbone, in the discovery and development of 
new drugs suitable to be applied in patients with neurodegenerative diseases, is still an 
unexplored field. However, the work performed by Brühlmann et al. [211] comprised the 
synthesis and evaluation of chromone derivatives (Fig 2.27 A) as potential AChE and 
MAO inhibitors. More recently it was shown that several benzyloxy substituted 
chromones possess high inhibitory activity towards human monoamine oxidase B and 
some of them showing reversibility [212-214]. A small library of (aminoalkoxy) chromones 
has been prepared and evaluated as DA D2 receptors agonists. The SAR studies 
revealed that the type of the substitutents at C-2 is an important feature to improve the 
desired activity and/or selectivity (Fig. 2.27 B) [215].  
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Figure 2.27 Chemical core of chromone derivatives tested as A: AChE and MAO inhibitors and B: Dopamine D2 
agonists. 
2.6 Methods of synthesis of simple chromones 
Generally, the total synthesis of simple chromones can be attained using starting 
materials that do not possess a pyran ring in their structure, such as phenols and 2-
hydroxyarylalkyl ketones. Despite the advances performed in synthetic strategies they 
are still the most cited in the literature. Yet, other building blocks, such as 2-
hydroxyarylalkynyl ketones and salicylic aldehydes have been recently used. As 
microwave assisted-synthesis is nowadays a valuable tool in the area of heterocyclic 
compounds efforts were performed to include this new technique in organic synthesis 
along the topic.  
2.6.1 Chromones from 2-hydroxyarylalkyl ketones 
The Baker-Venkatamaran rearrangement is perhaps the most charismatic 
methodology related with the chromone nucleus formation. This rearrangement takes 
place after the acylation of 2-hydroxyarylalkyl ketones, usually with acyl chlorides. In 
presence of a base such as potassium carbonate, the acyl intermediate rapidly 
undergoes a Baker-Venkatamaran rearrangement (scheme 2.1) leading to the 
formation of 1,3-dioxophenoxy intermediate. Classically, the intermediate compound is 
isolated and cyclised into the desired chromone under harsh conditions, such as 
heated concentrated sulphuric or glacial acetic acid. Among the huge diversity of 
chromone derivatives it is important to remark that a vast number of synthetic 2-
styrylchromone derivatives were obtained through this methodology [216-220]. 
 
A
B
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Scheme 2.1 Synthesis of chromones via Baker-Venkatamaran rearrangement. 
 
Several modifications have been proposed to this method. One is related with the 
possibility to perform the cyclisation process in situ, surpassing the isolation of the 
intermediate, using pyridine as a catalyst [221,222]. A recent example of this kind of 
approach is the synthesis of 2,8-disubstituted chromone derivatives and the use of 
diazabicyclo[5.4.0]undec-7-ene (DBU) and pyridine to promote the cyclization step [223]. 
Another variation of the method involves the acylation step: instead of using the 
conventional acyl chlorides some authors report the direct application of the carboxylic 
acids [224] or reaction with acid anhydrides as starting materials [225]. In addition, the use 
of other bases rather than potassium carbonate, such as metallic sodium [226], sodium 
alkoxide [204, 227-229], sodium hydride [204] and potassium or sodium hydroxide [230], has 
also been reported. Dyrager et al. [230] have synthesised 3-(4-fluorophenyl)-2-(4-
pyridyl)chromone derivatives through a microwave-assisted Baker–Venkatamaran 
rearrangement.  
Despite the ―popularity‖ of the Baker-
Venkatamaran rearrangement, one of the  first 
methodologies applied to the synthesis of 
chromones was the Claisen condensation. This 
well-known methodology was first described to 
obtain chromones by Kostanecki, Paul and 
Tambor for the synthesis of 7-ethoxy-4H-1-
benzopyran-2-carboxylic acid [231]. The 
construction of chromones based on this 
reaction may be performed in two steps (scheme 
2.2). The first involves the reaction of a strong 
base, traditionally sodium etoxide in ethanol, with 
a 2-hydroxyarylalkyl ketone and the formation of 
the corresponding enolate [232-234], which reacts 
with the appropriate carboxylic ester leading to 
the formation of 1,3-dioxophenoxy salt 
H+
Baker- Venkatamaran
rearrangement
NaOEt
H+
Scheme 2.2 Synthesis of chromones via 
Claisen condensation. 
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intermediate. The second step, the cyclization of the intermediate, is conventionally 
performed with heat and under acidic conditions [232-234]. An important group of 
chromone derivatives, the chromone 2-carboxylic acid or esters, may be synthesised 
by a variation of the Claisen condensation, also known as Kostanecki´ reaction [235]. 
Basically this methodology consists in the condensation of the 2-hydroxyacetophenone 
with diethyl oxalate in the presence of sodium ethoxide in ethanol (EtOH) followed by 
the oxopropanoate intermediate cyclisation under acidic conditions [236-239]. Other 
modifications to the synthesis of chromones via Claisen condensation were also 
reported [237, 240, 241]. Essentially, the reported modifications were focused in finding mild 
reaction conditions, such as the employment of triethylamine as solvent and base [242] 
although the use of other catalysts like LiH [243], NaH in THF [195] and NaH in pyridine 
[204, 244, 245] have also been described. Mozingo et al. [246] reported the use of metallic 
sodium as catalyst, instead of sodium etoxide in the synthesis of alkylchromones, such 
as 2-ethylchromone.  
More recently, several chromone derivatives, namely 2,6-dimethylchromone and 
2-methyl-6-chlorochromone, were synthesised under microwave irradiation. The 
synthetic strategy encompassed a Claisen condensation and a two-step procedure 
comprising the formation of the 1,3-dioxophenoxy intermediate and subsequent 
cyclisation under acidic conditions [247]. The major advantage of this synthesis is that 
microwave irradiation yields the intermediate within a reduced reaction time.  
Kostanecki, Robinson and their co-workers modified the Claisen condensation 
reaction to obtain diverse chromones, developing what is nowadays known as the 
Kostanecki-Robinson reaction. In this type of reaction the desired chromone is also 
obtained using 2-hydroxyarylakyl ketones as starting materials, by the reaction with 
aliphatic acid anhydrides in the presence of its corresponding sodium or potassium 
salts. This procedure obviates the need of the acidification step for ring closure, which 
is a significant advantage when compared with the classic Claisen reaction. It is 
noteworthy that the chromone formation does not involve a 1,3-dioxophenoxy 
intermediate, a requisite in the methods described so far. After the O-acylation of the 
starting material, as emphasized on the proposed reaction mechanism depicted in 
scheme 2.3, the arylakyl ketone undergoes enolisation with consequent acylation, 
affording an enolacetate intermediate, that after aldol intramolecular cyclisation 
followed by loss of water, delivers the final chromone [248] .  
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Scheme 2.3 Proposal mechanism of Kostanecki- Robinson reaction adapted from 
[248]
. 
 
The Kostanecki-Robinson reaction has been applied over the years in the 
synthesis of a large number of chromones [225, 249, 250]. Despite its wide application, this 
methodology possesses some drawbacks; one of them is related with the possibility of 
occurrence of the Baker-Venkatamaran rearrangement and consequent formation of 
unwanted compounds, namely 3-substituted chromones. This contingency has been 
explored and adjusted to obtain 3-acylchromones [226, 251]. 
Another important methodology employed in the chromone synthesis is the 
Vilsmeier-Haack reaction (scheme 2.4). Briefly, this reaction occurs between the 
appropriate 2-hydroxyalkylarylketone and the (Chloromethylene)dimethylammonium 
chloride (Vilsmeier reagent). The 
chloroiminium ion is formed in situ 
from the reaction of a N,N-
disubstituted formamide, such as 
dimethylformamide (DMF), with 
phosphorus oxychloride. In general, 
the reaction mechanism 
encompasses the formation of an 
non-substituted chromone as 
intermediate which suffers a second 
attack from the chloroiminium ion, 
giving rise to 3-substituted chromones [252].    
+
+
Scheme 2.4 Synthesis of chromones via  
Vilsmeier-Haack reaction. 
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This one pot procedure was applied to the synthesis of chromones for the first 
time in 1973 and has been widely used since then. Other similar formylating agents, 
such as DMF-dimethyl acetal, have been used as variants of the Vilsmeier-Haack 
reagent [253]. Recently, the synthesis of 3-
formylchromones by the Vilsmeier-Haack reaction 
was improved using microwave and solid-supported 
methods [254, 255].  
The synthesis of non-substituted chromones 
can be attained via benzopyrylium salt intermediates. 
In this condition, the 2-hydroxyacetophenones used 
as starting materials react with triethyl ortho formate 
and a strong mineral acid like perchloric acid 
(scheme 2.5) [154, 256-258]. Subsequently, the obtained 
benzopyrylium salt is converted to the chromone by 
heating the crude material in water. This method has 
been extended to the synthesis of 3-substituted 
chromones, such as  3-hydroxychromones [259] and 3-
methylchromones [260]. 
2.6.2 Synthesis of chromones from phenols 
In 1913, Simonis reported a reaction by which different types of phenols were 
condensed with β-ketoesters (e.g. ethyl acetoacetate) in the presence of phosphorus 
pentoxide (P2O5) to obtain chromones, instead of the corresponding coumarins, as a 
final product. This acid-catalyzed condensation became known as Simonis‘ reaction 
(scheme 2.6) [244]. The synthesis of chromones by Simonis reaction is usually operative 
when the phenol used as starting material has electron-withdrawing substituents, such 
as halogens or nitro groups. It was also found that the presence of alkyl substituents on 
the α-position of the β-ketoester can favor the formation of the chromone. Classically, 
phosphorus pentoxide is used as the condensing agent but sulfuric acid [143, 144, 261] or 
polyphosphoric acid [262] have also been employed. More recently, Eric Fillion et al.[263] 
described a successful synthetic strategy for the synthesis of 2-methylchromones by 
promoting the condensation of the suitable phenol with 5-(1-methoxyethylidene) 
Meldrum‘s acid in the presence of trifluoroacetic acid.  
Chromones can be obtained through the reaction of a phenol with acetylenic 
dicarboxylic acids, esters or with chlorofumaric acid, in basic conditions, such as 
metallic sodium or K2CO3. A particular intermediate is formed (scheme 2.6) which, in 
presence of sulphuric acid, perchloric acid or hydrogen fluoride cyclises to afford 
HClO4
H2O
Δ
+
Scheme 2.5 Synthesis of chromones 
via benzopyrylium salt intermediates. 
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chromone 2-carboxylic acid. This method, known as Ruhemann reaction, was largely 
applied to the synthesis of chromone-2-carboxylic acids and derivatives [235]. 
Ruhemann reaction was also used with slight modifications for the synthesis of 
flavones and styrylchromones [264]. In 1977, Lee and coworkers proposed a 
modification of the process using polyphosphoric acid as a catalyst [259].  
 
 
Scheme 2.6 Synthesis of chromones via Simonis and Ruhemann reactions. 
2.6.3 Synthesis of chromones from salicylic acids and derivatives 
Salicylic acid and its derivatives have been used as starting materials for the 
obtention of chromones by converting them into O-acyl(aroyl) derivatives. The 
subsequent reactions of these derivatives with tert-butyldimethylsilyl chloride in the 
presence of imidazole lead to the formation of the corresponding silyl esters. 
Chromones were then obtained in moderate to high yields, after reaction with 
(trimethylsilyl)methylenetriphenylphosphorane. This procedure corresponds to the first 
report of chromone synthesis via intramolecular Wittig ester carbonyl olefination 
(scheme 2.7A) [265]. 
Another interesting method comprises the reaction of activated salicylic 
derivatives with diethyl malonate giving intermediates that undergo subsequent 
hydrolysis and decarboxylation processes with formation of  2-methylchromones [266]. 
This type of chromones have also been obtained by the reaction of methyl salicylate 
with dimethylpenta-2,3-dienedioate, in the presence of KOtBu/BuOH (scheme 2.7B) 
[267]. 
Other applications of salicylic acid derivatives as starting materials have been 
reported in the literature, namely for the synthesis of chromones via the condensation 
P2O5
Or
H+
K2CO3
Simonis reaction Ruhemann reaction
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of methyl salicylate with bromocrotononitrile derivatives. The cyclisation of the vinyl 
ether intermediate was performed in a basic (NaH) medium (scheme 2.7 C)[ 268]. 
Functionalised 2-amino-3-cyano-4-chromones have also been obtained in a one 
pot procedure by reacting acetylsalicylic acid derivatives with N-hydroxybenzotriazole 
(HOBt) and malononitrile under basic conditions (NaH). The cyclisation step was 
attained with acid catalysis (HCl) (scheme 2.7 D) [269].  
 
 
Scheme 2.7 Synthesis of chromones from salicylic acids and derivatives. 
 
2.6.4 Synthesis of chromones via C-C cross coupling reactions  
Transition metal-catalysed 
reactions provide nowadays one of 
the most attractive methodologies for 
the formation of C–C and C-
heteroatom bonds. The application 
of these reactions has increased 
tremendously during the past 
decades and cross-coupling 
reactions became an important tool 
for synthetic chemists. Following this 
tendency, an attractive synthetic 
method has been developed for the 
synthesis of chromones involving a 
R2(CO)2O
TBMDS-Cl
R1=H
R1=CH3
R2=Me
HOBt
CH2(CN)2
Cl(=CCO2Me)2
KOtBu
H+, Δ
NaH
A
B
C
D
Pd catalyst
Alkyne
CO
Pd catalyst
Alkyne
[O]
A B C
Scheme 2.8 Synthesis of chromones via C-C cross coupling 
reactions. 
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one-pot Sonogashira-carbonylation-annulation reaction that involves the reaction of an 
ortho-iodophenol with a terminal acetylene, in the presence of a palladium complex, 
and the formation of an ortho-hydroxyarylalkynylketone intermediate avoiding the harsh 
reaction conditions (strong bases and acids or high temperature) used in the reactions 
above mentioned. The obtention of a chromone encompasses a cyclocarbonylation 
process which occurs in situ in the presence of carbon monoxide (Scheme 2.8 A) [78].  
The reaction proceeds in a short time and with very good yields. The use of microwave 
irradiation can speed up the process and substantially increasing the yields [270]. 
However, in particular situations a mixture of chromones and aurones can be obtained. 
This drawback can be minimized by the use of ionic liquids [270].  
The chromone formation by Sonogashira coupling with palladium catalysis was 
also performed by reacting an 2-methoxybenzoyl chloride with a terminal acetylene 
(Scheme 2.8 B) or an 2-methoxybenzaldehyde with a lithium acetylide (Scheme 2.8 C) 
[271]
. In all the cases, the intermediate compounds are 2-methoxyarylalkynylketones that 
after ring closure, performed by iodine monochloride (ICl), afford 3-iodochromones [272]. 
In summary, the obtention of chromones via palladium-mediated catalys is a simple 
and high efficient approach.  
An interesting alternative to the metal-catalysed C–C cross coupling reactions are 
the organocatalysed reactions. These reactions are eco-friendly as they are metal free 
and cost-effective, and are currently one of the most significant green chemistry 
research areas. In this context, N-heterocyclic carbenes (NHCs) have recently gained 
importance as catalysts of carbon–carbon bond formation. The use of NHCs catalysts 
was recently proposed for the synthesis of 3-aminochromones and other 3-substituted 
chromones, (scheme 2.9) [273-275]. NHCs catalysts were used with the purpose of 
promoting the intramolecular cross coupling between the aldehyde and the nitrile 
function (Scheme 2.9 A) or to enhance the intramolecular reaction of the aldehyde with 
an activated alkyne (Scheme 2.9 B). This latter reaction is a modification of the known 
intramolecular Stetter reaction [273-275]. 
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Scheme 2.9 Synthesis of chromones catalysed by NHCs. 
2.6.5 Synthesis of chromones from chromanones 
The formation of chromones starting from chromanones is not as common as the 
methodologies described above, essentially because the starting material is not easily 
available and the overall yields are often very low [259]. In fact, in the last three decades 
few studies have reported the application of chromanones to obtain chromones and, in 
most cases, the main approach involves the dehydrogenation or oxidation of the 
starting material. In order to achieve this goal, several oxidants such as iodide [276], 
vanadium pentoxide [277] and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) [278] 
were used. The reaction is often conducted in acidic medium[279]. Other catalysts, such 
as diethoxymethyl acetate [280, 281], thallium(III) [282] and the Lewis acids AlCl3 
[283] and 
BF3
-Et2O 
[284] have been also described. Furthermore, chromones can be obtained by 
dehydration of 2-hydroxychromanones through treatment with HCl in EtOH [285]. 
Dehydrobromination of the starting chromanone is another methodology applied to 
obtain chromones [286, 287]. This reaction is carried out in basic medium and can be 
performed using microwave irradiation [288]. 
2.6.6 Synthesis of chromones from other chromones 
As described before, direct and efficient chemical strategies have been 
developed for the synthesis of simple chromones. However, in recent years a 
modification on the strategy of synthesis of simple chromones has been observed, 
which is related with the need to speed up the drug discovery process, namely for 
structure-activity-relationships studies, in medicinal chemistry programs. In 
consequence, several simple functionalised chromones are by now commercially 
available and used as starting materials. The most common chromones used as 
starting materials have been found to be 6/7-hydroxy or methoxy, halo, methyl and 
formylchromones.  
NHCs
A B
NHCs
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The chemical core of chromone possesses three main areas suitable for the 
introduction of substituents: the aromatic ring and the positions 2- and 3- of the pyrone 
ring. Furthermore, a proper chemical function (e.g. hydroxy or methoxy) present in the 
benzopyran core of chromone allows the synthesis of several chromones derivatives 
with different substituents patterns. For instance, several benzylic, alkyl, and tioalkyl 
ethers have been obtained 
by the conventional 
methodologies for 
etherification, using as 
starting materials hydroxy or 
thio chromones (scheme 
2.10) [195, 214, 289].  
Interestingly, although the carboxylic acid is one of the most studied functions to 
obtain other classes of compounds, the use of the chromone carboxylic acids as 
starting materials is still very limited. 
The works performed in this field are 
mainly related with ester formation 
(e.g. methyl and ethyl esters) [231] or 
acyl halides as intermediates  for the 
synthesis of chromone carboxamides 
[290] (scheme 2.11). Other reported 
application of the chromone-2-
carboxylic acid is the synthesis of 2-
aminoalkyl chromones. The strategy to 
obtain this compounds comprises the formation of the corresponding methyl esters, 
reduction with NaBH4 with the synthesis  of the 2-hydroxymethylchromones 
subsequently transformed, by nucleofilic substitution, to 2-chloromethylchromones, that 
finally by reaction with several substituted amines will afford the correspondent   
aminoalkyl chromones.[291].  
A= O or S 
Scheme 2.10 Synthesis of chromones from hydroxyl or 
thiochromones. 
R1OH, H
+ SOCl2 or POCl3
Scheme 2.11 Synthesis of chromones from chromone 
carboxylic acids. 
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In addition, it is important 
to highlight the role of 3-
formylchromone and derivatives 
as starting materials to 
synthesise other chromones. 
The reduction or oxidation of the 
formyl function leads, 
respectively, to the formation of 
3-hydroxymethylchromones and 
chromone-3-carboxylic acids 
(scheme 2.12). The reduction 
process can be performed with a suspension of basic alumina in isopropanol [292] and 
the oxidation process with sodium chlorite in the presence of aminosulfonic acid[293]. 
Interestingly, this last strategy is the most cited to obtain the chromone-3-carboxylic 
acid while its isomer, chromone 2-carboxylic acid, is usually obtained by a classic 
methodology from 2-hydroxyarylalkylketones [293]. The presence of three electron-
deficient carbons (C-2, C-4 and CHO) on the 3-formylchromone structure makes this 
compound an exceptional starting material for several nucleofilic additions, which in 
turn can lead to a great diversity of derivatives. Taking advantage of these features, 
several heterocyclic substituted chromones were obtained, namely with aza [294, 295], 
diaza [170, 296], oxa [297] and dithiazole [298-302] groups  as well as vinyl chromone 
derivatives [303, 304] (scheme 2.13).  
 
Scheme 2.13 Synthesis of heterocyclic and vinyl substituted chromones. 
NaClO2, H3NSO3Al2O3, isoCH3OH
Scheme 2.12 Synthesis of chromones from 3-formylchromones. 
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A particular example of this type of nucleofilic additions is the synthesis of 
styrylchromones [218] by the condensation of a 3-formylchromone with malonic acid in 
pyridine, either with conventional heating or under microwave irradiation [305]. 
Additionally, styrylchromone derivatives can also be obtained by the condensation of 2-
methylchromones (scheme 2.14) with the benzaldehyde derivatives in presence of 
sodium methoxide or by the reaction of non-substituted chromones (scheme 2.14) with 
the Grinard reagents or by a C-C cross coupling palladium catalysed reaction [218]. 
 
 
Scheme 2.14 Synthesis of styrylchromones from other chromones. 
  
styrylchromones
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3.1 Chromone-2- and -3-carboxylic acids inhibit 
differently monoamine oxidases A and B 
Article from Bioorganic & Medicinal Chemistry Letters (2010), 20: 
2709–2712. 
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3.2 Chromone, a Privileged Scaffold for the  
Development of Monoamine Oxidase Inhibitors 
 Article from Journal Medicinal Chemistry (2011), 54: 5165–5173 
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3.3 Towards the Discovery of a Novel Class of 
Monoamine Oxidase Inhibitors:  
Structure–Property–Activity and Docking Studies 
on Chromone Amides. 
Article from ChemMedChem (2011), 6: 628–632. 
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3.4 Chromone 3-phenylcarboxamides as potent 
and selective MAO-B inhibitors 
Article reprinted from Bioorganic & Medicinal Chemistry Letters 
(2011), 21: 707–709. 
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3.5 In search for new chemical entities as 
adenosine receptor ligands: Development of 
agents based on benzo-γ-pyrone skeleton. 
Article reprinted from European Journal of Medicinal Chemistry 
(2012), 54, 914-918 
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3.6 Discovery of novel A3 adenosine receptor 
ligands based on chromone scaffold 
Article reprinted from Biochemical Pharmacology (2012), 84: 
21–29. 
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3.7 Combining QSAR classification models for 
predictive modeling of human monoamine 
oxidase inhibitors. 
Article from European Journal of Medicinal Chemistry (2013), 
59: 75-90. 
.  
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
103 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
104 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
105 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
106 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
107 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
108 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
109 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
110 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
111 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
112 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
113 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
114 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
115 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
116 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
117 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
118 
 
 
 
 
 
 
 
 
 
 
 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
119 
 
3.8 Synthesis and NMR studies of novel 
chromone-2-carboxamide derivatives. 
Article from Magnetic Resonance in Chemistry (2013), 51: 251–
254. 
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As previously described in chapter 2 simple chromones can be a valid scaffold for 
medicinal chemistry drug discovery programs. However, and despite the 
pharmacological properties so far described for simple chromones, their application in 
the field of neurodegeneratives diseases is still an open issue. The emergent need and 
pressing need for new therapeutic entities (NTEs), e.g. repurposed drugs, or new 
chemical entities (NCEs) for this type of diseases encouraged the design and 
development of the drug discovery project performed in this thesis. The project is 
mainly focused in the synthesis, development and biological evaluation of small, 
concise and diverse chromone libraries, comprising mainly functionalised chromones in 
2- and 3- positions, as new NCEs for neurodegenerative diseases, particularly PD. In 
the following sections will be adress the synthetic work executed and the biological 
evaluation of the synthesised libraries.  
4.1 Design, synthesis and structural characterisation of the 
diverse functionalized chromone libraries 
The generation of new lead compounds in drug discovery is nowadays a process 
mainly focused in the development of suitable chemical libraries providing reliable 
SARs. Chemical libraries are collections of different molecules sharing a common 
chemical core, which can be achieved by a diversity of approaches, for instance by 
combinatorial chemistry. This concept is a common practice in Pharma industry and it 
is often used to create a large variety of structurally related molecules in a short time, 
which are subsequently screened against a variety of targets by high throughput 
screening (HTS).  
Accordingly the conception of the chromone chemical libraries herein described 
were inspired in combinatorial chemistry and parallel synthesis, methodological 
concepts useful for the development of smaller and more specialized libraries based on 
a particular skeleton. Furthermore, the synthetic methodologies developed along this 
work were selected taking in account the possibility of the scale-up of the processes, 
using whenever possible available and cost-effective starting materials, straightforward 
one-pot synthetic and environment-friendly procedures, and choosing, if possible, 
simple and effective work-ups for product isolation and purification. 
The design of the chemical libraries based on the chromone scaffold 
encompasses the synthesis of several functionalised chromone derivatives, mainly 
located in the positions 2- or 3- of the pyrone ring but also in position 6/7- of the 
aromatic ring, such as alkyl esters, alcohols, carboxylic acids and amides.  The 
synthesised chromones are depicted in the tables 4.1, 4.2 and 4.3.  
 
Table 4.1. Chromone library I: ester, carboxylic acid, hydroxymethyl and formylchromone derivatives. 
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2-Substituted 
chromones 
 
3-Substituded 
chromones 
Compound Yield R R1 R2 Compound Yield 
1 81% COOC2H5 H H 2 60% 
3 52% COOC3H7 H H 4 60% 
5 60% COOC2H5 Cl H - - 
6 72% COOC2H5 H OCH3 - - 
7 62% COOH H OCH3 - - 
8 60% COOH Cl H 9 48% 
- - CHO Cl H 10 75% 
11 65% COOC2H5 Br H - - 
- - CHO Br H 12 85% 
13 43% CH2OH H H 14 48% 
15 55% COOC2H5 C6H5 H - - 
17 30% COOH C6H5 H - - 
- - CHO C6H5 H 18 30% 
 
 
Table 4.2 Chromone library II: phenylcarboxamide chromone derivatives. 
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2-Substituted 
chromones 
 
3-Substituded 
chromones 
Compound Yield R1 R2 R3 R4 R5 Compound Yield 
19 81% H H H H H 20 60% 
21 56% H H CH3 H H 22 45% 
23 40% CH3 H H H H 24 52% 
25 77% H CH3 H H H 26 54% 
27 75% CH3 CH3 H H H 28 63% 
29 67% H H C2H5 H H 30 56% 
31 69% H H C4H9 H H 32 49% 
33 85% H H OCH3 H H 34 30% 
35 90% OCH3 H H H H 36 72% 
37 65% H OCH3 H H H 38 42% 
39 50% H OCH3 OCH3 H H 40 45% 
41 62% H H 
 
H 42 40% 
43 51% H H OH H H 44 55% 
45 57% H OH OCH3 H H 46 45% 
47 65% H OH OH H H 48 50% 
49 30% H H NO2 H H 50 37% 
51 82% H H COOC2H5 H H 52 89% 
53 65% H H COOH H H 54 63% 
55 70% H H SCH3 H H 56 60% 
57 45% H H SO2CH3 H H - - 
58 26% H H NH2 H H - - 
59 50% H H CF3 H H 60 55% 
61 56% H H OCF3 H H 62 55% 
63 72% H H F H H 64 50% 
65 50% H H Cl H H 66 47% 
67 23% Cl H H H H 68 23% 
69 33% H Cl H H H 70 49% 
71 70% H H Br H H 72 64% 
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Table 4.2 (cont.): Chromone library II: phenylchromone carboxamide derivatives. 
2-Substituted 
chromones 
 
3-Substituded 
chromones 
Compound Yield R1 R2 R3 R4 R5 Compound Yield 
73 45% Br H H H H 74 25% 
75 60% H Br H H H 76 42% 
77 95% H H I H H 78 50% 
79 71% H H CN H H 80 50% 
 
Table 4.3: Chromone library III: alkyl, phenyl and heterocyclic chromone carboxamide derivatives. 
2-Substituted 
chromones 
 
3-Substituded 
chromones 
Compound Yield R R1 R2 Compound Yield 
81 35% 
 
H H 82 30% 
83 60% 
 
Cl H 84 45% 
85 67% 
 
Cl H 86 48% 
87 72% 
 
OCH3 H - - 
88 85% 
 
OCH3 H - - 
89 65% 
 
OCH3 H - - 
90 60% 
 
H H 91 30% 
92 35% 
 
H H 93 48% 
 
 
 
Table 4.3 (cont.): Chromone library III: alkyl, phenyl and heterocyclic chromone carboxamide derivatives. 
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2-Substituted 
chromones 
 
3-Substituded 
chromones 
Compound Yield R R1 R2 Compound Yield 
94 22% 
 
H H 95 35% 
96 55% 
 
H H 97 25% 
98 48% 
 
H H 99 10% 
100 33% 
 
H H 101 45% 
102 35% 
 
H H 103 22% 
104 52% 
 
H H 105 47% 
 
4.1.1 Synthesis of ester, carboxylic acid and formylchromone derivatives  
Some of the alkyl esters synthesised in this work (compounds 1-4, table 4.1.) 
were obtained by classical Fischer esterification (scheme 4.1 and article in section 3.7) 
from the commercially available chromone carboxylic acids and ethanol or propanol, in 
moderate to good yields (table 4.1.)  
 
 
Scheme 4.1 Synthesis of ester chromone derivatives by Fisher esterification. 
 
Additionally, the synthesis of the 6/7- substituted chromone esters (compounds 5, 
6, 11 and 15, table 4.1) were obtained by Claisen condensation of the appropriate 2-
hydroxyacetophenone with diethyl oxalate, in the presence of sodium ethoxide in 
H2SO4/R-OH
R= C2H5 or C3H7
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EtOH, followed by an intramolecular cyclisation, under acidic conditions (scheme 4.2 
and article in section 3.7). 
 
 
Scheme 4.2 Synthesis of ester chromone derivatives by Claisen condensation. 
 
The good yield obtained (>60%, table 4.1) and the single-step purification 
process, consisting of a simple recrystallization from ethyl acetate, validates the 
selection of the method. After purification, this chromone ester was submitted to a 
hydrolytic process, following the procedure of Hadjeri et al. [306] (article in section 3.7), 
yielding the corresponding carboxylic acids (compounds 7, 8 and 17, table 4.1).  
A different synthetic strategy was selected for the synthesis of 6-chloro-3-
chromone carboxylic acid and (compound 9, table 4.1), since it was described that 3-
chromone carboxylic acids can be easily obtained from 3-formylchromones [307]. 
Accordingly, 6-chloro-3-formylchromone (compound 10, table 4.1) was obtained 
via a Vilsmeier-Haack reaction, using 4-chloro-2-hydroxy acetophenone as the starting 
material, with a good yield (>70%, article in section 3.7.; scheme 4.3). The subsequent 
oxidation step, performed with sodium chlorite and sulfamic acid as oxidizing reagents, 
gave rise to the correspondent carboxylic acid in a moderate yield (48%, article in 
section 3.7; scheme 4.3).  
 
 
Scheme 4.3. Synthesis of 6-chloro-3-chromone carboxylic acid. 
 
The commercial availability of the starting material and the simplicity of the 
reaction and its work-up, were the main reasons to adopt this strategy to obtain the 
intended chromone carboxylic acid derivative. This methodology (Vilsmeier-Haack 
reaction) was also used to obtain compounds 12 and 18 (table 4.1.) using the 
appropriate 2-hydroxyacetophenone as starting materials. These types of 2- and 3- 
chromone derivatives, namely the ester, formyl and the carboxylic acid derivatives 
were subsequently used as starting materials to obtain other type of functionalized 
chromones. 
+
NaOEt/EtOH H+
R= Cl, Br, OCH3 or  C6H5
DMF, POCl3 NaClO2 in H2O
NH2SO3H in CH2Cl2
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4.1.2 Synthesis of hydroxymethylchromone derivatives 
The hydroxymethylchromone derivatives used along this project, namely the 2-
hydroxymethylchromone and the 3-hydroxymethylchromone (compounds 13 and 14 
respectively; table 4.1) were obtained by reduction processes from two different types 
of functionalized chromones: a chromone 2-ethyl ester derivative (synthesized by the 
method described in scheme 4.1) or the commercially available 3-formylchromone, 
respectively (scheme 4.4.). 
 
 
Scheme 4.4. Synthesis of hydroxymethylchromone derivatives. 
 
The 2-hydroxymethylchromone (scheme 4.4 A) was obtained by reducing the 
correspondent chromone ethyl ester using sodium borohydride (NaBH4) in methanol 
that promotes the transformation of the ester into a hydroxyl function (article in section 
3.7). It is noteworthy to mention that NaBH4  is not  a classic reagent for ester reduction 
under ambient conditions, mainly due to the slow reaction rate [308]. In this particular 
case, the procedure was adopted from Payard et al.[165] who have successfully 
obtained similar compounds in reasonable yields. The yields obtained in our studies 
are in accordance with those obtained by Payard et al.. These yields can somehow be 
explained by the presence in the chromone core of an α,β-unsaturated ketone system, 
which can reacts with NaBH4 formating side products.  
The synthesis of 3-hydroxymethylchromone (scheme 4.4 B) from 3-
formylchromone was based on the work of Maturana et al. [292], that used basic alumina 
in 2-propanol as reducing agent (article in section 3.7). The obtained yield for 
compound 14 (table 4.1) is in accordance with the reported by Maturana et al.. 
4.1.3 Synthesis of amide chromone derivatives 
The first synthetic approach used for the formation of the chromone 
carboxamides (table 4.2 and table 4.3) from chromone carboxylic acids (starting 
materials) encloses the activation of the carboxylic acid function with phosphonium 
coupling reagents, and consequent formation of phosphonium reactive intermediates, 
NaBH4
2-prOH
Basic alumina
MeOHA
B
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followed by a condensation reaction with aniline derivatives. (scheme 4.5.; articles in 
sections 3.1.- 3.8.) 
 
 
Scheme 4.5. Synthesis of amide chromone derivatives. 
 
The generation of the phosphonium intermediates was accomplished by using O-
benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) 
(figure 4.1.) as a coupling agent, that was after substituted by O-benzotriazol-1-
yloxytris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) (Fig. 4.1.), to avoid 
the generation of toxic hexamethylphosphoramide (HMPA), a by-product of BOP [309]. 
Another phosphonium coupling agent, bromotripyrrolidinophosphonium 
hexafluorophosphate (PyBrOP) (Fig. 4.1.), was used to obtain the tertiary amide 
reported in the work reprinted in section 3.7. In fact, it was described that BOP and 
PyBOP are not suitable coupling 
agents for condensation reactions 
with hindered aminoacids[310]. As an 
alternative, the use of PyBrOP or 
chlorotripyrrolidinophosphonium 
hexafluorophosphate (PyClOP) (Fig. 
4.1) is strongly advised. Therefore, 
the unproductive results obtained 
with PyBOP in the condensation of 
the chromone-2-carboxylic acid with 
the N-methyl aniline, was evaded by 
the use of PyBrOP (article in section 
3.7).  
Driven by the preliminary biological results, new chromone carboxamides were 
designed in order to progress the SAR studies, while costless, easy and eco-friendly 
reactions were sought for their synthesis. Although the amidation reaction promoted by 
phosphonium coupling reagents is a one-pot step synthesis, without the need of 
intermediate isolation, the high cost of the reagents, the laborious and time consuming 
purification steps boost the search of other synthetic strategies. It was found that the 
activation the chromone-2-carboxylic acid with phosphoryl chloride (POCl3), gave rise 
to a rapid in situ formation of the acyl chloride intermediate, which without isolation is 
R= H, Cl, OCH3
BOP
PyBOP
PyClOP PyBrOP
Figure 4.1. Phosphonium coupling agents. 
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used in the N-acylation step. In fact, after the subsequent addition of the intended 
amine derivative, and under microwave irradiation for a short period (5 min), several of 
the desired chromone carboxamides were obtained. The purification processes 
involves only filtration and recrystallization techniques (article in section 3.8.). However, 
despite the inherent advantages, this strategy revealed itself unproductive for the 
synthesis of chromone-3-carboxamides. Additional research is on progress to optimize 
the technique and attain good results with 3-substituted chromones.  
4.1.4 Structural characterization of the chromone derivatives 
All the synthesised compounds (tables 4.1, 4.2 and 4.3) were fully characterized 
by 1D NMR (1H, 13C and DEPT) techniques and electron impact mass spectrometry 
(EI/MZ). Additionally, 2D NMR (COSY, HMBC and HMQC) studies were also 
performed. A database for the unambiguous identification of the chromone-2-
carboxamide library was successful attained using 1D and 2D NMR (article in section 
3.8). 
During the structural elucidation of the compounds of the chromone 3-
carboxamide library some dilemmas arise due to the appearance of non-expected 
signals in the NMR spectra of all the compounds of the series, namely the splitting 
pattern of the NH of the carboxamide and of H-2 signals and also in the appearance of 
double signals in the region corresponding to the CONH and C-2 carbons (Table 2 of 
the article in section 3.3). To justify the presence of this type of signals in the spectra, a 
dynamic study was performed, using diverse spectroscopic and theoretical tools, which 
was reported on the paper in section 3.3. The data acquired in the NMR experiments 
as well as in theoretical approaches, gave rise to the hypothesis that a possible 
intramolecular hydrogen bond may be presented in solution, with the putative formation 
of tautomers. However, it seems also plausible the existence of amide rotamers in 
solution, as the amide function often demonstrates to have this property [311]. These 
hypotheses were investigated by performing focused NMR studies, like the use of 
deuterated water to evaluate the exchangeability of the proton and by the acquisition of 
the NMR data at temperatures higher than 300 K, to speed up the exchange of 
rotamers. Unfortunately the gathered data is still inconclusive and further investigations 
are still needed.  
 
4.2 Chromone a valid scaffold for the development of MAO-B 
inhibitors 
Since the introduction of L-deprenyl in 1975 as an antiparkinsonian drug the 
search for new of MAO-B inhibitors has been strengthened. As a result, rasagiline was 
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launched in 2006 for monotherapy in early Parkinson's disease or as an adjunct 
therapy in more advanced cases. Rasagiline has received singular attention not only 
duo to its MAO-B inhibitory activity, but also for its neuroprotective properties. Although 
both mentioned drugs are highly potent selective inhibitors of MAO–B they are 
irreversible inhibitors, permanently deactivating the enzyme.  
So, the development of selective and reversible MAO-B inhibitors is still an open 
issue and the goal of numerous medicinal chemistry programs. Accordingly, several 
privileged structures, such as pyrazoles, xanthones, coumarins and hydrazine 
derivatives have been used in the process of discovery and development (chapter 1). 
To validate the chromone structure as a scaffold for the development of new 
MAO-B inhibitors, we have selected for the first approach two functionalized 
chromones: chromone 2- and 3- carboxylic acids (article in section 3.1). To note that 
chromones without substituents doesn‘t not display MAO inhibitory activity[212]. The 
results of the screening assays towards human MAO isoforms (hMAO-A and hMAO-B) 
showed that the presence and position of the COOH group on benzopyrone ring has a 
significant influence in the biological activity. In fact, when the COOH substituent is 
located in the position 3 of the benzopyrone ring a selective inhibition of hMAO-B 
isoform (IC50 hMAO-B 0.048 ± 0.0026 nM; SI >2083) was observed. In contrast, the 
chromone isomer, with the carboxylic function in position 2, has no activity for both 
MAO isoforms (article in section 3.1).  
Molecular modeling and docking studies were at that point performed to assess 
the putative interactions between the chromone isomers and MAOs enzyme active 
sites that can explain the experimental data. These studies were performed in close 
collaboration with Stefano Alcaro‘s group, from the Department of Pharmacology, 
Faculty of Pharmacy, University ―Magna Græcia‖ in Catanzaro, Italy.  
The publication of the crystallographic structures of MAO-B in 2002 [312, 313] and 
MAO-A in 2004[314] provided useful support tools to better understand the features that 
regulate the ligand recognition by both MAO isoforms. Apart from punctual differences 
in the amino acids sequences, since both human isoforms share approximately 70% of 
homology, one of the most relevant discoveries from the acquired x-ray data, was the 
structural differences of the active site of both isoforms, namely the bipartite cavity of 
hMAO-B against the monopartite cavity of hMAO-A[315]. In fact, it was demonstrated 
that the active site of hMAO-B is formed by two hydrophobic cavities, the ―substrate or 
catalytic cavity‖ and the ―entrance cavity‖ [312]. These two pockets are separated by four 
amino acids residues namely, Tyr326, Ile199, Leu171 and Phe168 and transient 
movements of these amino acids must occur for the ligand to reach the catalytic site of 
the enzyme[312, 313, 315]. Furthermore, interactions with Ile199 and Tyr326 seem quite 
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important for inhibitor recognition by hMAO-B [316]. The major differences regarding the 
active site of hMAO-B and hMAO-A have been identified, mainly the hMAO-B Ile199 
and Tyr326 that are substituted in hMAO-A, by Phe208 and Ile335 respectively[312].  
The molecular docking data points out the existence of different interactions 
between the chromones and the active site of MAO isoforms, namely the presence of a 
hydrogen bond established between chromone 3-carboxylic acid and hMAO-B amino 
acid Tyr 326 (Fig. 4.2), that was not present in the docking process of chromone 2-
carboxylic acid. This outcome was the engine for the design and development of a 
small chromone library, mainly based on chemical modifications similarly performed at 
positions 2 or 3 of the pyrone ring (tables 4.1. 4.2. and 4.3.) that was screened towards 
MAO isoforms. The results were reported in papers reprinted in sections 3.2., 3.3., and 
3.4.. 
The preliminary SAR studies allow concluding that i) the modification of the 
carboxylic acid moiety by an ester or an alcohol function gives rise to inactive 
compounds (article in section 3.7.); ii) when the carboxylic acid was replaced by an 
alkyl/cycloalkyl or aryl amide function in position 3 of the chromone ring, several active 
compounds were obtained with a diverse inhibitory activity outline, although alkyl 
chromone carboxamides are less active than aryl ones (articles in sections 3.2., 3.3, 
and 3.4.); iii) the presence of a phenyl ring located on the 3-carboxamide side chain 
enhances MAO-B potency of inhibition (article in section 3.3.).  
The overall data allow concluding that, in general, when the carboxamide 
substituent is allocated at position 3 of the chromone scaffold a hMAO-B inhibitory 
activity is noticed whereas the corresponding isomeric chromone-2- carboxamides are 
inactive in respect to both MAO isoforms. This tendency is similar to that obtained for 
the chromone carboxylic acids suggesting that the amide function can be also an 
important feature as it can 
also play a role in the 
establishment of a hydrogen 
bond with the active site of 
the enzyme. 
After the preliminary 
SAR study the chromone 
carboxamide library was 
amplified to optimize the 
compound in potency and 
selectivity as a MAO-B 
inhibitor. Accordingly, the exocyclic aromatic ring was decorated with different type of 
Figure 4.2. Virtual docking of chromone-3-carboxylic acid into the 
hMAO-B catalytic site (figure extracted from article in section 3.1). 
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substituents located in different positions (see section 4.2). The data obtained so far 
confirms the superior activity and selectivity of all the chromone-3-carboxamide 
derivatives towards MAO-B isoform. Additionally, it was also concluded that the 
potency and selectivity of the chromone-3-carboxamides was modulated by 
substituents located in the para position of the exocyclic aromatic ring. The most 
promising compounds are highlighted in Fig. 4.3. Moreover, reversibility studies were 
performed over two of most promising chromones carboxamides (compounds 44 and 
66, Fig. 4.3). These studies revealed that the mentioned chromone carboxamides 
behave as quasi-reversible MAO-B inhibitors (article in section 3.2.).  
 
Figure 4.3. Chemical structures of five of the best chromone-3 carboxamides and their inhibitory activity 
towards hMAO-B. 
 
hMAO-B IC50 (µM)= 0.068 0.0030
SI˃1471
Compound 22
hMAO-B IC50 (µM)= 0.063 0.0042
SI˃1585
Compound 66
hMAO-B IC50 (µM)= 0.069 0.0054
SI˃1449
Compound 78
hMAO-B IC50 (µM)= 0.064 0.0054
SI=74 
Compound 44
hMAO-B IC50 (µM)= 0.0674 0.0032
SI=110
Compound 46
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The theoretical calculated binding modes of N-phenyl, N-cyclohexyl N-propyl, 
(Fig. 4.4) and N-4´-chlorophenyl (compound 66, Fig. 4.3) chromone-3-carboxamides 
were visually inspected and similar interactions were found for all of the cited 
compounds (article in section 
3.3). The proposed binding 
modes of this type of chromone 
inhibitors reveal that the 
carboxamide side chain is 
located toward the FAD 
cofactor and the -pyrone ring 
located towards the pocket 
entrance. All the studied 
compounds showed a 
hydrogen bond interaction with 
Tyr326 residue involving either 
the ether present in the -
pyrone ring (Compound 105, 
Fig. 4.4) and the sp2 oxygen 
from the carboxamide moiety (compound 66, Fig. 4.3; compounds 20 and 91, Fig. 4.4). 
Remarkably, it was observed that all the studied compounds are somehow correlated 
with Cys172, an amino acid residue present in the entrance cleft of hMAO-B [312]. 
Focusing the attention in the N-(4-(chlorophenyl)-chromone-3-carboxamide (compound 
66, Fig. 4.3), one of the 
most active hMAO-B 
inhibitors (article in section 
3.2), it is possible to 
highlight the presence of 
hydrogen bonds with 
Cys172 and Tyr326 (Fig. 
4.5) and other productive 
interactions of the 
hydrophobic side chain of 
the compound with Ile199, 
Pro102, Phe103, and 
Leu167.  
 
Figure 4.5 Virtual docking of N-(4-(chlorophenyl)-chromone-3-
carboxamide into the hMAO-B catalytic site (figure extracted from 
article in section 3.2). 
hMAO-B IC50 (µM)= 37.69 1.68
SI˃2.7
Compound 105
hMAO-B IC50 (µM)= 0.93 0.062
SI˃107
Compound 91
hMAO-B IC50 (µM)= 0.40 0.022
SI˃250
Compound 20
Figure 4.4 Chemical structures of N-phenyl (compound 20), N-
cyclohexyl (compound 91) and N-propyl (compound 105) 
chromone-3-carboxamides and their inhibitory activity towards 
hMAO-B. 
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In summary, the molecular docking studies have shown that the productive 
interactions detected between the chromone-3-phenylcarboxamides and the hMAO-B 
isoform occur in non-conserved a.a. residues of the active site of hMAO-A isoform, a 
variance that can explain their selectivity towards hMAO-B isoform. 
The overall data obtained in this rational drug discovery program allows to 
conclude that chromone-3-carboxamide is a valid scaffold for the development of MAO-
B inhibitors and that a subsequent project of lead optimisation must be implemented to 
attain potent, selective and reversible MAO-B inhibitors. 
4.3 Chromone a valid scaffold for the development of 
adenosine receptors ligands 
One of the drug discovery approaches accepted at the present time as a putative 
solution to find an effective therapy for multifactorial pathoetiological diseases, such as 
neurodegenerative disorders and cancer, encompasses a change of the ―one disease, 
one target, one molecule‖ paradigm, This new point of view embraces the concept of 
―promiscuous‖ drugs and consequently encloses the design and development of new 
drugs that act simultaneously in more than one target. Accordingly, and taking 
advantage of the MAO-B inhibition outline exhibited by chromone carboxamides, it was 
decided to perform the screening of the same chromone library towards other target. 
As adenosine receptors (ARs) are a recognized target for the development of drugs for 
the treatment of diverse maladies, namely in neurodegenerative diseases, as 
described in section 2.4 of this thesis, they have been selected to accomplish the 
objective. So, the affinity of the chromone ligands towards the four subtypes AR was 
evaluated. The data was first acquired by outsourcing with an academic research 
centre, and then by a fruitful collaboration with Professor Karl-Norbert Klotz, from the 
Institute of Pharmacology and Toxicology, University of Wurzburg. Consequently, the 
methods used to assess the AR binding capacity encompass different procedures, a 
fact that can explain the apparent data differences found in the published articles 
(articles in sections 3.5. and 3.6.). 
One of the most glaring discrepancies is related with the data assessed for A2B 
receptor. In fact, in one of the papers (article in section 3.5) the binding affinity was 
acquired using radioligand assays and in the other one (article in section 3.6) by the 
measurement of adenylyl cyclase activity (indirect method). The binding affinity data 
acquired for the other three receptors have been performed by radioligand competition 
experiments in both assays. Nevertheless, the type of cells and radioligands used in 
the cited assays was different (table 4.4).  
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Table 4.4. Radioligands binding assays conditions. 
Adenosine 
receptor 
Type of cells Radioligands 
 Article in section 3.5 Article in section 3.6 Article in section 3.5 Article  in section 3.6 
A1 
CHO 
transfected cells 
CHO transfected cells 
[
3
H]DPCPX [
3
H]CCPA 
A2A HeLa transfected 
cells 
[
3
H]ZM241385 [
3
H]NECA 
A3 [
3
H]NECA [
3
H]HEMADO 
 
Despite the pointed differences, and excluding the data acquired for A2B, a 
comparative analysis for some chromone carboxamides disclosed the existence of the 
same structural trends: i) a higher affinity for A3 AR subtype and ii) a higher selectivity 
for the A3 AR subtype receptor  for chromone-2-carboxamides.  
In summary, the data acquired so far allow concluding that chromone carboxylic 
acids (the starting building blocks) display no significant binding affinity for all ARs and 
that the introduction of carboxamide type substituents result in compounds with a 
diverse affinity and selectivity profile towards human A1, A2A and A3 ARs. In general, 
the introduction of a phenylcarboxamide substituent at position 2, with or without 
substituents in the exocyclic aromatic moiety (e.g. 3‘,4‘-dimethoxyphenylcarboxamide) 
generates compounds that bind selectively to A3 AR. However, one can highlight that 
when the phenylcarboxamide substituent is located at position 3 the compounds are 
generally more potent, but less selective. 
Focusing our attention on the data described on the article in section 3.6., other 
significant SAR conclusions can be carried out. In general, it is possible to assume that 
the positions of the substituent on the pyran ring of the chromone scaffold, the type of 
amide (aromatic, cyclic or aliphatic) as well as the presence of electron donors or 
withdrawing groups on the exocyclic aromatic substituent have a marked effect on their 
binding affinity towards ARs.  
A closer look through the results showed that, despite being more active, 
chromone-3-carboxamides are generally less selective than their corresponding 
isomers at position 2 (see tables 1 and 2 of the article in section 3.6.) and that in 
general, the presence of withdrawing groups causes a decrease or loss of the binding 
affinity towards A3 ARs. Nevertheless, the presence of chlorine or nitro substituents at 
the para position of the chromone-3-phenylcarboxamides seems to improve the affinity 
for A2A and A3 ARs subtypes. The presence of electron donating groups at the 
exocyclic aromatic ring of the chromone carboxamides induced different performances 
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in the two isomeric series. In fact, all the chromone-2-phenylcarboxamides with 
donating groups displayed a significant binding affinity towards A3 AR. The most 
remarkable improvement of potency is related with the introduction of a methoxy group, 
when compared to that of the non-substituted 2-phenylcarboxamide. Interestingly, the 
introduction of a hydroxy function at the para position of the exocyclic aromatic ring led 
to enhanced affinity binding towards A2A AR, although with a reduced selectivity ratio. In 
contrast, the chromone-3-phenylcarboxamides with donating groups showed in general 
an improvement of their binding affinity potencies for all the ARs, when compared with 
the non-substituted one. An exception for this trend comprises the chromone-3-(4´-
methoxyphenyl) carboxamide that only exhibits improvement in the binding affinity 
potency towards A3 AR.  
The overall results obtained with chromone carboxamide library allow concluding 
that this type of chromones can work as a valuable starting point for development of 
new ligands for A3 AR. Some chromone carboxamides (Fig. 4.6) have an interesting 
binding affinity towards A2A AR, despite the lack of selectivity regarding A1 and A3 ARs. 
It is expected that their optimisation can lead to the discovery of new ligands for this 
receptor subtype in a foreseeable future. 
 
 
Figure 4.6. Chemical structures of three of the best chromone-3 carboxamides as A2A AR ligands. 
 
hA2A AR Ki (nM)= 6850
SI (hA2A/ hA1)= 0.8
SI (hA2A/ hA3)= 1.9
Compound 46
hA2A AR Ki (nM)= 12,400
SI (hA2A/ hA1)= 1.06
SI (hA2A/ hA3)= 1.9
Compound 40
hA2A AR Ki (nM)= 17,400
SI (hA2A/ hA1)= 0.7
SI (hA2A/ hA3)= 1.1
Compound 66
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The studies were also accomplished by a receptor-driven molecular modelling 
investigation performed in collaboration with the Molecular Modeling Section (MMS), 
Department of Pharmaceutical Sciences, University 
of Padua. It was concluded that in general chromone 
carboxamides exhibit different binding poses inside 
the binding pockets either of hA2A or hA3 ARs, a 
condition that can somehow explain the different Ki 
obtained in the pharmacological assays. This type of 
molecular docking studies (fig 4.7.) were thoroughly 
performed for one of the most active chromone 
carboxamide (compound 46, Fig. 4.6) towards A2A 
and A3 ARs subtypes in order to disclose the nature of interactions with the binding 
pocket of each receptor. Additionally, the per residue electrostatic and hydrophobic 
contributions were also calculated (article in section 3.6.). 
The homology models, the mutagenesis studies and the A2A AR recently 
determined crystallographic structure[317] have brought to the light the existence of 
several amino acids residues that are important for ligand binding, namely Ile80, Val84, 
Leu85, Thr88, Gln89, Ile135, Leu167 (EL2), Phe168 (EL2), Asn181, Phe182, Val186, 
Trp246, Leu249, His250, Asn253, Ile274, Ser277, His278. Furthermore, the 
crystallographic structure of the hA2A AR in complex with the potent and selective 
antagonist ZM241385 (Fig. 4.8) reinforced the importance of Glu169, His250, Asn253, 
Ile274, Phe168, Met177 and Leu249 amino acids residues in the binding of the ligand 
with the receptor[317]. Interestingly, in the A2A AR model used in our studies the most 
active chromone carboxamide revealed putative interactions with two key amino acid 
residues establishing an H-bond interaction with Asn253 and a stabilizing interaction 
Figure 4.7. Hypothetical binding modes of one of our most active compound obtained after docking 
simulations: (A) inside the hA2A AR binding site; (B) inside the hA3 AR binding site. (Figure extracted from 
article in section 3.6) 
 
Figure 4.8. Chemical structure of 
ZM241385 
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with Phe168 (EL2). In addition, a weak H-bond interaction with Tyr271 as well as 
hydrophobic interactions with some aa residues of the pocket, including Leu85, Trp246, 
Leu249, Tyr271 and Ile274, were also detected. However, no interaction with Glu169 
(EL2) an important residue in ligand recognition was detected. The information 
gathered in the analysis of the electrostatic contribution per residue and in the 
hydrophobic interaction score patterns strengthen the hypothesis that the most 
stabilizing contributions are due the H-bond with Asn253 and the hydrophobic 
interactions of the ligand with Phe168 (EL2). The acquired data is of utmost 
significance for the optimisation step of this chromone carboxamide. 
Despite the enormous advances in X-ray crystallography of proteins the high 
resolution structural information on the active and inactive states of GPCRs is still 
uncovered. In fact, the 3D structural information available so far for this type of 
receptors is still largely based on rhodopsin homology models[317]. However, as 
previously mentioned, the recent publication of the crystal structure of the hA2A AR in 
complex with a high-affinity subtype-selective antagonist, ZM241385 has provided a 
new template for the 3D structure of hA3 AR. 
The homology model of the hA3 AR used in this work was built up by Moro and 
co-workers [155, 318]. In accordance with the aim of project ligand binding studies were 
performed for the most active compound (the same used for hA2A molecular docking 
studies, Fig. 4.7). The most important binding features were related with the presence 
of two H-bond interactions with Asn250 and Phe168 (EL2), and hydrophobic 
interactions between the ligand and some residues of the binding site, such as Leu91, 
Trp243, Leu246 and Leu264 (article in section 3.6.). 
Comparing the data gathered for the hA2A and the hA3 ARs one can infer that the 
electrostatic contribution associated to the Asn residue is much more prevalent for the 
hA3 AR ligand complex and in that way can compete with the stabilizing interaction with 
Phe168 found for A2A AR ligand complex. This assumption is in accordance with the 
experimental data (hA2A AR Ki (nM)= 6850 and hA3 AR Ki (nM)=3680) which showed a 
lower Ki value for hA3 AR.  
As known in medicinal chemistry programs, the prerequisite of interdisciplinary 
artwork encompass a natural delay on the attainment of the results, a problematic that 
is aggravated when the project is focused on the discovery and development of dual-
target drugs. So, when expecting data acquisition the chromone carboxamide library 
was amplified and the affinity of the ligands towards ARs was evaluated. In general, the 
new chromones display a superior affinity for A3 AR ligands and so this part of the 
unpublished work was reported in the thesis. 
FCUP 
Chromone: a valid scaffold in Medicinal Chemistry 
143 
 
4.4 Chromone-2-carboxamide a valid scaffold for the 
development of A3 AR ligands  
Currently, a growing number of evidences related with all four AR subtypes as 
potential drug targets for cancer have been gathered, placing the A2A and A3 subtypes 
as the most promising ones[319]. As adenosine plays a crucial role in the cell 
progression pathway, either during apoptosis or during cytostatic state, it has been 
postulated that high levels of extracellular adenosine can have a profound impact on 
the growth of solid tumours masses [319]. Paradoxically, the drug discovery process 
performed so far encompasses either agonist or antagonist AR ligands and both of 
them have shown encouraging results [320, 321].  As mentioned in section 2.4.2 the 
search for new A3 AR agonists has been mainly based in adenosine and xanthine 
scaffolds, with other classes of compounds having a less significant expression in the 
drug discovery projects. However, the strategy to develop new A3 AR antagonists 
involved also a diversity of scaffolds, such as flavonoids, 1,4-dihydropyridines and 
pyridine derivatives and isoquinoline and quinazoline derivatives [322, 323].  
On the other hand, it has been recently proposed that there is a significant 
inverse relationship between PD and certain types of cancers[312, 314] These two 
pathologies can be faced as the result of opposite abnormal cell signalling, with an 
irreversible cell death in PD and cell overproliferation resistant to death in 
carcinogenesis. The research in the field is now gathering evidences to attest the 
existence of an overlap between the molecular pathways implicated in these two 
distinct processes[310, 311, 313].  
Epidemiological studies have shown that some cancers, namely melanoma and 
breast cancer, occur frequently in PD patients, when compared with the controls[324]. To 
note that the possibility of an increased risk of melanoma in PD patients associated 
with the L-Dopa therapy has being discarded over the years by the scientific 
community[315] and that other variables, such as molecular, genetic  and environmental 
factors are emerging as probable explanations for the epidemiological data[317]. Albeit 
of the exact mechanisms underlying the observed cancer-PD association are not still 
fully understood, the study of the signalling pathways and mechanisms for both 
diseases can unveil new approaches in the discovery and development of new 
chemical entities as anti-cancer and/or as antiparkinsonian drugs. In fact, the work of 
Hebron et. al.[318] that describes nilotinib, a drug approved by the US Food and Drug 
Administration (FDA) in 2007 to leukemia treatment, as a possible drug for Parkinson 
disease therapy was the pioneer . 
In the search for dual-target compounds for PD based on the chromone scaffold 
it was observed that some compounds of the library displayed a noticeable affinity and 
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selectivity for A3 AR subtype, and that when the library was amplified the new 
chromones exhibited a superior affinity for A3 AR ligands (unpublished data). So, as 
mentioned before, this new data was included in the thesis and discussed. 
As it was already mentioned in section 4.3 it was concluded that chromone 2-
carboxamides were more selective for A3 AR subtype than their isomers at position 3 
and that the preliminary SAR studies have shown that the presence of electron donors 
or withdrawing groups on the aromatic exocyclic substituent modulate their affinity and 
selectivity towards the ARs. After the amplification of the chromone 2-carboxamide 
library and biological evaluation towards ARs a more well-founded SAR have been 
established. Some of the chemical modifications have been constructed on structural 
changes of the compounds highlighted in Fig. 4.9 involving the synthesis of their ortho 
and meta structural isomers (table 4.2).  
 
 
 
Figure 4.9. Chemical structures of mono substituted chromone-2-carboxamides, their corresponding hA3 Ki and 
selective index (SI). 
 
 
The binding affinity data of compounds 23, 25, 35, 37, 67 and 69 (table 4.5.) 
show that the location of the substituents, namely at para position of the exocyclic 
aromatic ring, are somewhat important for ligand recognition.  
 
 
 
 
 
 
Table 4.5 Affinity (Ki, nM) of monosubstituted chromone-2-carboxamides in radioligand binding assays at 
hARs. 
hA3 AR Ki (nM)= 15,800
SI (hA1/ hA3) ˃ 6.3
SI (hA2A/ hA3) ˃ 6.3
SI (hA2B/ hA3 ˃ 1.9
Compound 21
hA3 AR Ki (nM)= 9,580
SI (hA1/ hA3) ˃ 10
SI (hA2A/ hA3) ˃ 10
SI (hA2B/ hA3 ˃ 3.1
Compound 33
hA3 AR Ki (nM) ˃ 100,00
Compound 65
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Other structural modifications have been based on the results obtained for the 
compounds highlighted in figure 4.10, compound 45 (articles in sections 3.2 and 3.5) 
and the newly synthesised compounds (27 and 41) represented in table 4.6 were also 
evaluated as potential ligands for ARs and the (data is described in table 4.6.).   
 
 
Compound 
A1 AR 
Ki (nM) 
A2A AR 
Ki (nM) 
A2B AR 
Ki (nM) 
A3 AR 
Ki (nM) 
23 
 
˃100,000 ˃100,000 ˃10,000 
21,800 
(17,300– 
27,500) 
25 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
35 
 
˃100,000 ˃100,000 ˃10,000 ˃30,000 
37 
 
˃100,000 ˃30,000 ˃10,000 ˃30,000 
67 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
69 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
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Figure 4.10. Chemical structures of di-exocyclic substituted chromone-2-carboxamides, their corresponding 
hA3 Ki and selective index (SI). 
 
Table 4.6. Affinity (Ki, nM) of disubstituted chromone-2-carboxamides in radioligand binding assays at hARs. 
 
Analysing the data reported in table 4.6., one can conclude that the modifications 
based on compound 47, which have two hydroxyl groups in meta and para positions of 
the exocyclic aromatic ring, were able to produce a compound with a better A3 AR 
subtype binding profile, when compared with the compounds presented in figure 4.10. 
and with those described in Fig. 4.9. However, it is important to note that the selectivity 
index of this compound between A1 AR and A3 AR is only around 1.3 resulting in a loss 
of selectivity towards A3 AR.  
To inspect the role of electron donating and withdrawing groups on the binding 
affinity towards ARs, new chromone-2-carboxamides were synthesized (table 4.7. and 
4.8.). The data obtained so far reinforces the hypothesis (article in section 3.6.) that the 
hA3 AR Ki (nM)= 15,400
SI (hA1/ hA3) ˃ 6.5
SI (hA2A/ hA3) ˃ 2.3
SI (hA2B/ hA3 ˃ 1.9
Compound 45
hA3 AR Ki (nM)= 27.900
SI (hA1/ hA3) ˃ 3.6
SI (hA2A/ hA3) ˃ 3.6
SI (hA2B/ hA3 ˃ 1.1
Compound 39
Compound 
A1 AR 
Ki (nM) 
A2A AR 
Ki (nM) 
A2B AR 
Ki (nM) 
A3 AR 
Ki (nM) 
27 
 
˃100,000 ˃100,000 ˃10,000 
20,000 
(16,537– 
24,253) 
41 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
47 
 
7,366 (4,290–
12,700) 
39,727 
(32,099–
49,168) 
˃10,000 
5,735 (5,192–
6,335) 
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presence of withdrawing groups in the exocyclic phenyl group (compounds 51, 63, 71 
and 77, tables 4.7) has a negative effect in the binding affinity toward all ARs.  
 
Table 4.7. Affinity (Ki, nM) of monosubstituted chromone-2-carboxamides with withdrawing groups in 
radioligand binding assays at hARs. 
 
Furthermore, the presence of a straight alkyl chain with a length higher than CH3 
(compounds 29 and 31, table 4.8) leads to a complete loss of activity towards A3 AR 
subtype. Interestingly, the replacement of the OCH3 (compound 33 table 4.2 and Fig. 
4.9) by its bioisoster SCH3 (compound 55, table 4.8.) or by a NH2 group (compound 58, 
table 4.8) led to a total loss of activity for all the ARs.  
To examine the importance of the existence of a secondary amide for the 
biological activity, tertiary chromone 2-carboxamides (compounds 81 and 100 table 
4.9.) have been synthesised. However, a decrease or loss of binding affinity towards 
hA3 AR (table 4.9.) was observed, when compared with monosubstituted N-phenyl 
chromone 2-carboxamide (Ki =14,200 nM, article in section 3.6). 
 
 
 
 
 
Compound 
A1 AR 
Ki (nM) 
A2A AR 
Ki (nM) 
A2B AR 
Ki (nM) 
A3 AR 
Ki (nM) 
51 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
63 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
71 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
77 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
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Table 4.8. Affinity (Ki, nM) of monosubstituted chromone-2-carboxamides with donating groups in radioligand 
binding assays at hARs. 
 
Table 4.9. Affinity (Ki, nM) of tertiary chromone-2-carboxamides in radioligand binding assays at hARs. 
 
The replacement of the phenyl ring by other type of heteroaromatic rings gave 
rise to the compounds 92, 94, 96 and 98 (table 4.10). The results for the binding affinity 
assays (table 4.10) show that the introduction of a heterocyclic aromatic ring, directly 
linked to NH of the carboxamide (compounds 94, 96, 98) produced active but non 
selective ligands for A1, A2A and A3 ARs. The presence of a CH2 spacer between the 
carboxamide function and the exoheterocyclic ring (compound 92, table 4.9.) led to a 
Compound 
A1 AR 
Ki (nM) 
A2A AR 
Ki (nM) 
A2B AR 
Ki (nM) 
A3 AR 
Ki (nM) 
29 
 
˃100,000 ˃100,000 ˃10,000 ˃30,000 
31 
 
˃100,000 ˃100,000 ˃10,000 ˃30,000 
55 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
58 
 
˃10,000 ˃10,000 ˃10,000 ˃10,000 
      
Compound 
A1 AR 
Ki (nM) 
A2A AR 
Ki (nM) 
A2B AR 
Ki (nM) 
A3 AR 
Ki (nM) 
81 
 
˃100,000 ˃100,000 ˃10,000 
26,177 
(21,177– 
31,614) 
100 
 
˃100,000 ˃100,000 ˃10,000 ˃100,000 
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compound without affinity to A3 and A2B ARs but with affinity towards A1 and A2A ARs 
with a selective ratio A1/A2A of 0.7. This data and the results obtained for non-aromatic 
carboxamides (article in section 3.6) reinforce the hypothesis that the aromatic 
exocyclic ring is an important requisite for the binding affinity of chromone carboxamide 
ligands towards A3 AR.  
 
Table 4.10. Affinity (Ki, nM) of heterocyclic chromone-2-carboxamides in radioligand binding assays at hARs. 
 
On the other hand, the modification of the carboxamide moiety (Compound 102, 
table 4.10) by introducing of a thio bioisostere, and maintenance of the substituent 4‘-
CH3 on the phenyl exocyclic ring, led to a compound twice as potent for A3 AR (Ki 
=8,630 nM) than compound 21 (Ki =15,800 nM) (Fig. 4.9) However, and despite the 
pronounced affinity potency improvement, a loss of specificity was observed as, 
surprisingly, a similar binding potency for A2B AR (Ki =8,630 nM) (unpublished data) 
was noticed.  
From the overall data obtained so far it is concluded that the type and position of 
the donor groups at the exocyclic phenyl ring of the chromone 2-carboxamides is 
constrained, as only 4‘-CH3 and the 4‘-OCH3 substituents are able to enhance the 
Compound 
A1 AR 
Ki (nM) 
A2A AR 
Ki (nM) 
A2B AR 
Ki (nM) 
A3 AR 
Ki (nM) 
92 
 
11,976 
(8,450–
17,000) 
18,499 
(11,700–
29,100) 
˃10,000 ˃100,000 
94 
 
17,328 
(11,400–
26,300) 
15,092 
(9,160–
24,900) 
˃10,000 
11,923 
(10,900–
13,100) 
96 
 
8,178 (5600–
11,900) 
10,354 
(8,040–
13,300) 
˃10,000 
1,307 (982–
1,740) 
98 
 
10,203 
(7,620–
13,700) 
18,892 
(13,300–
26,900) 
˃10,000 
10,687 
(8,610–
13,100) 
102 
 
˃100,000 ˃100,000 
8,630 
(5,740–
13,000) 
8,214 
(5,130–
13,100) 
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affinity and specificity towards A3 AR, when compared with the non-substituted N-
phenyl chromone 2-carboxamide. In fact, the lack of binding affinity observed for the 
four positional isomers (compounds 29, 25, 35 and 37, table 4.5) corroborates the 
hypothesis that the location of substituents in the para position is vital to preserve the 
A3 AR affinity. Interestingly, it was observed that the presence of two hydroxyl groups 
(compound 47, table 4.6.) at the exocyclic aromatic ring led to an enhancement of the 
binding affinity to A3 AR. This compound is one of the most active compounds with a 
hA3 AR Ki=5,735 nM being around 2.5 fold more potent than the non-substituted N-
phenyl chromone 2-carboxamide (hA3 AR Ki= 14,200 nM article in section 3.6). Finally, 
it is important to highlight the compound 96, the most potent compound so far tested, 
with an A3 AR Ki =1,307 nM, being 6 and nearly 8 times more selective for A3 than A1 
and A2A, respectively.  
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5.1 Concluding remarks and future perspectives 
The discovery and development of a new drug is a long, laborious and 
demanding process. Its successful development generally relies on the availability of a 
continuous pipeline of novel molecules (New Chemical Entities, NCE's). However, a de 
novo drug discovery campaign has considerable drawbacks, mainly related to the 
challenge of selecting a satisfactory library for the establishment of preliminary 
structure−activity relationships. This process can be fast-tracked taking advantage of 
the concept of privileged structure. Despite the identification of many molecular 
frameworks performed so far, there is still a restricted number of core scaffolds and 
fragments for the design of chemical libraries directed for specific targets [13].  
In this project, the chromone scaffold was validated as a useful framework for the 
development of new lead compounds for Parkinson disease. In this context, a pioneer 
dual-target (MAO-B and A2A AR) drug discovery and development project based on the 
chromone scaffold has been implemented. To attain this goal, chromone libraries were 
planned and diversity-oriented synthetic strategies have been applied. 
The results obtained so far highlight two promising chromone carboxamides (Fig. 
5.1) that show potent and selective MAO-B inhibition and also display binding affinity 
towards A2A AR. 
The preliminary SAR studies, reinforced by the molecular modelling data, afford 
important  clues to get-
up-and-go the 
research. In fact, it was 
demonstrated that, in 
general, only the 
chromone-3-
carboxamide series 
present MAO-B 
inhibitory activity, and 
that some chromones 
display remarkable 
potency/selectivity ratios (Compound 22, IC50=0.068±0.0030 µM,SI˃1471; Compound 
46= 0.0674±0.0032 µM SI=110; compound 66, IC50= 0.063±0.0042 µM, SI˃1585 and 
compound 78, IC50 = 0.069±0.0054 µM SI˃1449, to cite some). Interestingly, it was 
found that the two of the best chromone-3-carboxamides (Fig. 5.1.) displayed 
simultaneously affinity towards the A2A AR subtype.  
 In a foreseeable future it will be important to perform fine molecular 
modifications in order to attain more robust SARs studies that hopefully will result in the 
hMAO-B IC50 (µM)= 0.0674 0.0032
SI=110
Compound 46
hMAO-B IC50 (µM)= 0.063 0.0042
SI˃1585
Compound 66
hA2A AR Ki (nM)= 6850
SI (hA2A/ hA1)= 0.8
SI (hA2A/ hA3)= 1.9
hA2A AR Ki (nM)= 17,400
SI (hA2A/ hA1)= 0.7
SI (hA2A/ hA3)= 1.1
Figure 5.1. Chemical structures of two of the best chromone-3-carboxamides 
as inhibitors of hMAO-B isoform and as ligands of hA2A ARs. 
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optimisation of above mentioned compounds. The improvement of either the A2A AR 
potency as well as their selectivity towards this AR subtype is therefore a forthcoming 
aim in future research. Moreover, the results obtained for the chromone-2-
carboxamides as selective ligands towards A3 AR, provide a new scaffold for the 
development of new anti-cancer drugs. Therefore, efforts should also be performed to 
carry this particular research a step further. The introduction of substituent(s) on the 
aromatic chromone ring, bioisosteric replacements on the carboxamide moiety, and the 
modification of the substitution pattern on the exocyclic aromatic ring are some of the 
likely modifications that can be made. 
Additionally, the balance between physiochemical and pharmacokinetic 
properties is not only a critical point in the design of new drugs, but also a feature of 
upmost importance in the design, synthesis and development of NCEs for 
neurodegeneratives diseases. In fact, blood-brain barrier permeability is a crucial 
requirement to obtain centrally active drugs that are able to reach their target(s) within 
the CNS, making the development of these drugs a pressing and challenging 
endeavour. Accordingly, as a complement to the synthetic artwork and in order to 
enhance the preliminary SARs studies, screening assays will be important to attain 
several physicochemical and pharmacokinetic properties (e.g. solubility, permeability, 
metabolic stability) of the most promising compounds. 
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